Covered recipient · General Payments record
MANISH SHARMA
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$23.93
1 record · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Education | $23.93 | 1 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Myovant Sciences Inc. | $23.93 | 1 |
Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
MANISH SHARMA
NPI 1790819332 · CMS profile ID 1126262
Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology
GRAND RAPIDS, MI
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1790819332?year=2021&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- MANISH SHARMA, NPI 1790819332, CMS profile ID 1126262. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1790819332?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). MANISH SHARMA, NPI 1790819332, CMS profile ID 1126262. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1790819332?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- MANISH SHARMA, NPI 1790819332, CMS profile ID 1126262, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1790819332?year=2021&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
1 matching record · $23.93 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–1 of 1.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Myovant Sciences Inc. | $23.93 | 03/24/2021 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834990035 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $373.20 | 2 |
| PY2025 | Principal investigator | $4,235,582.65 | 823 |
| PY2024 | Recipient | $4,269.33 | 9 |
| PY2024 | Principal investigator | $3,811,534.65 | 643 |
| PY2023 | Recipient | $3,810.00 | 6 |
| PY2023 | Principal investigator | $3,149,687.09 | 471 |
| PY2022 | Principal investigator | $3,302,171.04 | 339 |
| PY2021 | Recipient | $7,293.02 | 4 |
| PY2021 | Principal investigator | $2,076,760.51 | 208 |
| PY2020 | Recipient | $7,900.00 | 2 |
| PY2020 | Principal investigator | $1,132,655.23 | 78 |
| PY2019 | Principal investigator | $1,305,040.24 | 61 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
825 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $542.70 | 12/31/2025 | Non-covered Recipient Entity START MIDWEST LLC | A Phase 1 First-in-Human, Open-Label Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABBV-711 as a Monotherapy or in Combination with Budigalimab (ABBV-181) in Adult Subjects with Advanced Squamous Tumors | No dispute reported | 06/30/2026 | 1202532737 |
| Principal investigator 1 | ABBVIE INC. | $600.00 | 12/31/2025 | Non-covered Recipient Entity START MIDWEST LLC | A Phase 1 First-in-Human, Open-Label Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABBV-303, as Monotherapy and in Combination with Budigalimab (ABBV-181), in Adult Subjects with Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202532739 |
| Principal investigator 1 | ABBVIE INC. | $600.00 | 12/31/2025 | Non-covered Recipient Entity START MIDWEST LLC | A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1202532743 |
| Principal investigator 1 | ABBVIE INC. | $600.00 | 12/31/2025 | Non-covered Recipient Entity START MIDWEST LLC | A Phase 1 First in Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-400 as Monotherapy and in Combination with Bevacizumab in Adult Subjects with Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202532745 |
| Principal investigator 1 | ABBVIE INC. | $101.25 | 12/31/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202532935 |
| Principal investigator 1 | ABBVIE INC. | $490.05 | 12/31/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202533945 |
| Principal investigator 1 | ABBVIE INC. | $2,728.76 | 12/31/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202533947 |
| Principal investigator 1 | ABBVIE INC. | $750.00 | 12/31/2025 | Non-covered Recipient Entity START MIDWEST LLC | A Global First-in-Human Study in NSCLC, HNSCC and Solid Tumors with Azirkitug (ABBV-514) as a Single Agent and in Combination with Budigalimab or Bevacizumab | No dispute reported | 06/30/2026 | 1202534439 |
| Principal investigator 1 | PFIZER INC. | $1,622.52 | 12/29/2025 | Non-covered Recipient Entity START Midwest START Midwest | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228714829 |
| Principal investigator 1 | ABBVIE INC. | $3,152.25 | 12/24/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202531848 |
| Principal investigator 1 | ABBVIE INC. | $3,152.25 | 12/24/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202531850 |
| Principal investigator 1 | ABBVIE INC. | $4,233.60 | 12/24/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202531902 |
| Principal investigator 1 | ABBVIE INC. | $1,544.40 | 12/24/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202531926 |
| Principal investigator 1 | ABBVIE INC. | $2,115.45 | 12/24/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202531960 |
| Principal investigator 1 | ABBVIE INC. | $3,152.25 | 12/24/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202531982 |
| Principal investigator 1 | Genmab U.S., Inc. | $719.89 | 12/24/2025 | Non-covered Recipient Entity SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS | First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235935315 |
| Principal investigator 1 | ABBVIE INC. | $229.50 | 12/22/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202531580 |
| Principal investigator 1 | ABBVIE INC. | $229.50 | 12/22/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202531586 |
| Principal investigator 1 | ABBVIE INC. | $1,925.00 | 12/22/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202531594 |
| Principal investigator 1 | ABBVIE INC. | $2,813.27 | 12/22/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202531628 |
| Principal investigator 1 | ABBVIE INC. | $67.50 | 12/19/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202531500 |
| Principal investigator 1 | PFIZER INC. | $1,070.00 | 12/19/2025 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07820435 AS MONOTHERAPY AND IN COMBINATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228806704 |
| Principal investigator 1 | Stemline Therapeutics Inc. | $21,900.00 | 12/19/2025 | Non-covered Recipient Entity START MIDWEST, LLC | A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer | No dispute reported | 06/30/2026 | 1244134807 |
| Principal investigator 1 | Stemline Therapeutics Inc. | $1,500.00 | 12/19/2025 | Non-covered Recipient Entity START MIDWEST, LLC | A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer | No dispute reported | 06/30/2026 | 1244134812 |
| Principal investigator 1 | Stemline Therapeutics Inc. | $1,100.00 | 12/19/2025 | Non-covered Recipient Entity START MIDWEST, LLC | A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer | No dispute reported | 06/30/2026 | 1244134816 |
| Principal investigator 1 | ABBVIE INC. | $935.00 | 12/18/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202531082 |
| Principal investigator 1 | ABBVIE INC. | $202.50 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530684 |
| Principal investigator 1 | ABBVIE INC. | $202.50 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530686 |
| Principal investigator 1 | ABBVIE INC. | $58.05 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530688 |
| Principal investigator 1 | ABBVIE INC. | $5,817.15 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530690 |
| Principal investigator 1 | ABBVIE INC. | $490.05 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530692 |
| Principal investigator 1 | ABBVIE INC. | $101.25 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530694 |
| Principal investigator 1 | ABBVIE INC. | $75.60 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530696 |
| Principal investigator 1 | ABBVIE INC. | $2,338.20 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530698 |
| Principal investigator 1 | ABBVIE INC. | $54.00 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530702 |
| Principal investigator 1 | ABBVIE INC. | $1,998.00 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530706 |
| Principal investigator 1 | ABBVIE INC. | $47.25 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530708 |
| Principal investigator 1 | ABBVIE INC. | $75.60 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530718 |
| Principal investigator 1 | ABBVIE INC. | $472.50 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530720 |
| Principal investigator 1 | ABBVIE INC. | $982.80 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530722 |
| Principal investigator 1 | ABBVIE INC. | $1,788.75 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530724 |
| Principal investigator 1 | ABBVIE INC. | $982.80 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530726 |
| Principal investigator 1 | ABBVIE INC. | $75.60 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530728 |
| Principal investigator 1 | ABBVIE INC. | $472.50 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530730 |
| Principal investigator 1 | ABBVIE INC. | $87.75 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530732 |
| Principal investigator 1 | ABBVIE INC. | $172.80 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530734 |
| Principal investigator 1 | ABBVIE INC. | $445.50 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530736 |
| Principal investigator 1 | ABBVIE INC. | $445.50 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530738 |
| Principal investigator 1 | ABBVIE INC. | $445.50 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530740 |
| Principal investigator 1 | ABBVIE INC. | $47.25 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530742 |
| Principal investigator 1 | ABBVIE INC. | $101.25 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530744 |
| Principal investigator 1 | ABBVIE INC. | $982.80 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530746 |
| Principal investigator 1 | ABBVIE INC. | $7,425.00 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530748 |
| Principal investigator 1 | ABBVIE INC. | $101.25 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530750 |
| Principal investigator 1 | ABBVIE INC. | $101.25 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530752 |
| Principal investigator 1 | ABBVIE INC. | $445.50 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530754 |
| Principal investigator 1 | ABBVIE INC. | $75.60 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530756 |
| Principal investigator 1 | ABBVIE INC. | $67.50 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530758 |
| Principal investigator 1 | ABBVIE INC. | $87.75 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530760 |
| Principal investigator 1 | ABBVIE INC. | $101.25 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530762 |
| Principal investigator 1 | ABBVIE INC. | $101.25 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530764 |
| Principal investigator 1 | ABBVIE INC. | $202.50 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530766 |
| Principal investigator 1 | ABBVIE INC. | $982.80 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530768 |
| Principal investigator 1 | ABBVIE INC. | $75.60 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530770 |
| Principal investigator 1 | ABBVIE INC. | $7,425.00 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530772 |
| Principal investigator 1 | ABBVIE INC. | $101.25 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530774 |
| Principal investigator 1 | ABBVIE INC. | $2,338.20 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530776 |
| Principal investigator 1 | ABBVIE INC. | $1,788.75 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530778 |
| Principal investigator 1 | ABBVIE INC. | $7,425.00 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530788 |
| Principal investigator 1 | ABBVIE INC. | $75.60 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530790 |
| Principal investigator 1 | ABBVIE INC. | $1,788.75 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530792 |
| Principal investigator 1 | ABBVIE INC. | $810.00 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530794 |
| Principal investigator 1 | ABBVIE INC. | $67.50 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530796 |
| Principal investigator 1 | ABBVIE INC. | $7,425.00 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530798 |
| Principal investigator 1 | ABBVIE INC. | $445.50 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530800 |
| Principal investigator 1 | ABBVIE INC. | $101.25 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530802 |
| Principal investigator 1 | ABBVIE INC. | $1,998.00 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530804 |
| Principal investigator 1 | ABBVIE INC. | $75.60 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530806 |
| Principal investigator 1 | ABBVIE INC. | $472.50 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530808 |
| Principal investigator 1 | ABBVIE INC. | $174.15 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530810 |
| Principal investigator 1 | ABBVIE INC. | $1,998.00 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530812 |
| Principal investigator 1 | ABBVIE INC. | $101.25 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530814 |
| Principal investigator 1 | ABBVIE INC. | $101.25 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530816 |
| Principal investigator 1 | ABBVIE INC. | $1,788.75 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530818 |
| Principal investigator 1 | ABBVIE INC. | $49.95 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530820 |
| Principal investigator 1 | ABBVIE INC. | $183.60 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530822 |
| Principal investigator 1 | ABBVIE INC. | $472.50 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530824 |
| Principal investigator 1 | ABBVIE INC. | $490.05 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530826 |
| Principal investigator 1 | ABBVIE INC. | $101.25 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530828 |
| Principal investigator 1 | ABBVIE INC. | $445.50 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530830 |
| Principal investigator 1 | ABBVIE INC. | $810.00 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530836 |
| Principal investigator 1 | ABBVIE INC. | $1,998.00 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530838 |
| Principal investigator 1 | ABBVIE INC. | $1,998.00 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530840 |
| Principal investigator 1 | ABBVIE INC. | $101.25 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530842 |
| Principal investigator 1 | ABBVIE INC. | $490.05 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530844 |
| Principal investigator 1 | ABBVIE INC. | $40.50 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530846 |
| Principal investigator 1 | ABBVIE INC. | $810.00 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530848 |
| Principal investigator 1 | ABBVIE INC. | $7,425.00 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530850 |
| Principal investigator 1 | ABBVIE INC. | $810.00 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530852 |
| Principal investigator 1 | ABBVIE INC. | $445.50 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530854 |
| Principal investigator 1 | ABBVIE INC. | $490.05 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530856 |
| Principal investigator 1 | ABBVIE INC. | $117.45 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530858 |
| Principal investigator 1 | ABBVIE INC. | $75.60 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530860 |
| Principal investigator 1 | ABBVIE INC. | $72.90 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530862 |
| Principal investigator 1 | ABBVIE INC. | $75.60 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530864 |
| Principal investigator 1 | ABBVIE INC. | $2,338.20 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530866 |
| Principal investigator 1 | ABBVIE INC. | $490.00 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530868 |
| Principal investigator 1 | ABBVIE INC. | $445.50 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530870 |
| Principal investigator 1 | ABBVIE INC. | $75.60 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530872 |
| Principal investigator 1 | ABBVIE INC. | $62.10 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530874 |
| Principal investigator 1 | ABBVIE INC. | $45.90 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530876 |
| Principal investigator 1 | ABBVIE INC. | $40.50 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530878 |
| Principal investigator 1 | ABBVIE INC. | $75.60 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530880 |
| Principal investigator 1 | ABBVIE INC. | $445.50 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530882 |
| Principal investigator 1 | ABBVIE INC. | $13,647.27 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530884 |
| Principal investigator 1 | ABBVIE INC. | $1,788.75 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530886 |
| Principal investigator 1 | ABBVIE INC. | $810.00 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530888 |
| Principal investigator 1 | ABBVIE INC. | $101.25 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530890 |
| Principal investigator 1 | ABBVIE INC. | $101.25 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530892 |
| Principal investigator 1 | ABBVIE INC. | $101.25 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530894 |
| Principal investigator 1 | ABBVIE INC. | $2,338.20 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530896 |
| Principal investigator 1 | ABBVIE INC. | $982.80 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530898 |
| Principal investigator 1 | ABBVIE INC. | $75.60 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530900 |
| Principal investigator 1 | ABBVIE INC. | $490.05 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530902 |
| Principal investigator 1 | ABBVIE INC. | $101.25 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530904 |
| Principal investigator 1 | ABBVIE INC. | $86.40 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530906 |
| Principal investigator 1 | ABBVIE INC. | $490.05 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530908 |
| Principal investigator 1 | ABBVIE INC. | $101.25 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530910 |
| Principal investigator 1 | ABBVIE INC. | $101.25 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530912 |
| Principal investigator 1 | ABBVIE INC. | $1,998.00 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530914 |
| Principal investigator 1 | ABBVIE INC. | $490.05 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530916 |
| Principal investigator 1 | ABBVIE INC. | $445.50 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530918 |
| Principal investigator 1 | ABBVIE INC. | $13,647.31 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530920 |
| Principal investigator 1 | ABBVIE INC. | $472.50 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530922 |
| Principal investigator 1 | ABBVIE INC. | $1,788.75 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530924 |
| Principal investigator 1 | ABBVIE INC. | $982.80 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530926 |
| Principal investigator 1 | ABBVIE INC. | $101.25 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530928 |
| Principal investigator 1 | ABBVIE INC. | $490.05 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530930 |
| Principal investigator 1 | ABBVIE INC. | $445.50 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530932 |
| Principal investigator 1 | ABBVIE INC. | $810.00 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530934 |
| Principal investigator 1 | ABBVIE INC. | $101.25 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530936 |
| Principal investigator 1 | ABBVIE INC. | $445.50 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530938 |
| Principal investigator 1 | ABBVIE INC. | $472.50 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530940 |
| Principal investigator 1 | ABBVIE INC. | $490.05 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530942 |
| Principal investigator 1 | ABBVIE INC. | $2,338.20 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530944 |
| Principal investigator 1 | ABBVIE INC. | $202.50 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530946 |
| Principal investigator 1 | ABBVIE INC. | $490.10 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530950 |
| Principal investigator 1 | ABBVIE INC. | $54.00 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530952 |
| Principal investigator 1 | ABBVIE INC. | $101.25 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530954 |
| Principal investigator 1 | ABBVIE INC. | $7,425.00 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530956 |
| Principal investigator 1 | ABBVIE INC. | $101.25 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530958 |
| Principal investigator 1 | ABBVIE INC. | $2,338.20 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530960 |
| Principal investigator 1 | ABBVIE INC. | $7,425.00 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530962 |
| Principal investigator 1 | ABBVIE INC. | $101.25 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530964 |
| Principal investigator 1 | Genmab U.S., Inc. | $825.00 | 12/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1235935526 |
| Principal investigator 1 | PFIZER INC. | $9,120.14 | 12/16/2025 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228815695 |
| Principal investigator 1 | ABBVIE INC. | $935.00 | 12/15/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530398 |
| Principal investigator 1 | ABBVIE INC. | $1,005.00 | 12/15/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530480 |
| Principal investigator 1 | ABBVIE INC. | $1,135.00 | 12/15/2025 | Non-covered Recipient Entity START MIDWEST LLC | A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202530486 |
| Principal investigator 1 | ABBVIE INC. | $1,005.00 | 12/15/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530488 |
| Principal investigator 1 | Tanabe Pharma America, Inc. | $96,452.83 | 12/15/2025 | Non-covered Recipient Entity START Midwest, LLC | A Phase I/II, Dose-escalation and Dose-optimization Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy ofMT-4561in Patients With Various Advanced Solid Tumors and to Evaluate Effect ofMT-4561on Pharmacokinetics of Oral Midazolam | No dispute reported | 06/30/2026 | 1243870903 |
| Principal investigator 1 | ABBVIE INC. | $87.75 | 12/12/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530324 |
| Principal investigator 1 | ABBVIE INC. | $5,275.15 | 12/12/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530326 |
| Principal investigator 1 | ABBVIE INC. | $445.50 | 12/12/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530330 |
| Principal investigator 1 | ABBVIE INC. | $445.50 | 12/12/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530334 |
| Principal investigator 1 | ABBVIE INC. | $87.75 | 12/12/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530340 |
| Principal investigator 1 | ABBVIE INC. | $445.50 | 12/12/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530342 |
| Principal investigator 1 | ABBVIE INC. | $2,250.45 | 12/12/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202530346 |
| Principal investigator 1 | ModernaTX, Inc. | $10,195.89 | 12/12/2025 | Non-covered Recipient Entity SOUTH TEXAS ACCELERATED | A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors | No dispute reported | 06/30/2026 | 1252984900 |
| Principal investigator 1 | ABBVIE INC. | $3,015.00 | 12/11/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202529972 |
| Principal investigator 1 | ABBVIE INC. | $445.50 | 12/05/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202529184 |
| Principal investigator 1 | ABBVIE INC. | $151.20 | 12/05/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202529186 |
| Principal investigator 1 | ABBVIE INC. | $2,338.20 | 12/05/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202529188 |
| Principal investigator 1 | ABBVIE INC. | $1,647.50 | 12/05/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202529190 |
| Principal investigator 1 | ABBVIE INC. | $810.00 | 12/05/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202529192 |
| Principal investigator 1 | ABBVIE INC. | $1,788.75 | 12/05/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202529196 |
| Principal investigator 1 | ABBVIE INC. | $6,007.50 | 12/05/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202529198 |
| Principal investigator 1 | ABBVIE INC. | $467.10 | 12/05/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202529200 |
| Principal investigator 1 | ABBVIE INC. | $1,998.00 | 12/05/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202529202 |
| Principal investigator 1 | ABBVIE INC. | $2,025.00 | 12/04/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202526428 |
| Principal investigator 1 | ABBVIE INC. | $54.00 | 12/04/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202526430 |
| Principal investigator 1 | ABBVIE INC. | $101.25 | 12/04/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202526432 |
| Principal investigator 1 | ABBVIE INC. | $101.25 | 12/04/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202526436 |
| Principal investigator 1 | ABBVIE INC. | $202.50 | 12/04/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202526438 |
| Principal investigator 1 | ABBVIE INC. | $32.13 | 12/04/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202526444 |
| Principal investigator 1 | ABBVIE INC. | $2,058.75 | 12/04/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202526446 |
| Principal investigator 1 | ABBVIE INC. | $67.50 | 12/04/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202526448 |
| Principal investigator 1 | ABBVIE INC. | $1,200.00 | 12/04/2025 | Non-covered Recipient Entity START MIDWEST LLC | A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202526450 |
| Principal investigator 1 | ABBVIE INC. | $2,268.00 | 12/04/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202526454 |
| Principal investigator 1 | PFIZER INC. | $67,324.13 | 12/04/2025 | Non-covered Recipient Entity START Midwest LLC | PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY | No dispute reported | 06/30/2026 | 1228815909 |
| Principal investigator 1 | ABBVIE INC. | $4,549.34 | 12/03/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202526336 |
| Principal investigator 1 | ABBVIE INC. | $1,005.00 | 12/03/2025 | Non-covered Recipient Entity START MIDWEST LLC | A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202526338 |
| Principal investigator 1 | Genmab U.S., Inc. | $6,220.80 | 12/03/2025 | Non-covered Recipient Entity START MIDWEST LLC | A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1235935530 |
| Principal investigator 1 | Genmab U.S., Inc. | $16,100.00 | 12/03/2025 | Non-covered Recipient Entity START MIDWEST LLC | A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1235935550 |
| Principal investigator 1 | Genmab U.S., Inc. | $12,441.60 | 12/03/2025 | Non-covered Recipient Entity START MIDWEST LLC | A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1235935557 |
| Principal investigator 1 | Genmab U.S., Inc. | $21,263.85 | 12/03/2025 | Non-covered Recipient Entity START MIDWEST LLC | A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1235935564 |
| Principal investigator 1 | Genmab U.S., Inc. | $6,220.80 | 12/03/2025 | Non-covered Recipient Entity START MIDWEST LLC | A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1235935576 |
| Principal investigator 1 | Genmab U.S., Inc. | $400.00 | 12/03/2025 | Non-covered Recipient Entity START MIDWEST LLC | A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1235935581 |
| Principal investigator 1 | Genmab U.S., Inc. | $25,034.48 | 12/03/2025 | Non-covered Recipient Entity START MIDWEST LLC | A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1235935588 |
| Principal investigator 1 | Genmab U.S., Inc. | $6,220.80 | 12/03/2025 | Non-covered Recipient Entity START MIDWEST LLC | A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1235935604 |
| Principal investigator 1 | Genmab U.S., Inc. | $1,200.00 | 12/03/2025 | Non-covered Recipient Entity START MIDWEST LLC | A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1235935607 |
| Principal investigator 1 | Genmab U.S., Inc. | $12,441.60 | 12/03/2025 | Non-covered Recipient Entity START MIDWEST LLC | A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1235935618 |
| Principal investigator 1 | Genmab U.S., Inc. | $1,264.00 | 12/03/2025 | Non-covered Recipient Entity START MIDWEST LLC | A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1235935626 |
| Principal investigator 1 | Genmab U.S., Inc. | $1,121.85 | 12/03/2025 | Non-covered Recipient Entity START MIDWEST LLC | A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1235935635 |
| Principal investigator 1 | Genmab U.S., Inc. | $16,100.00 | 12/03/2025 | Non-covered Recipient Entity START MIDWEST LLC | A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1235935643 |
| Principal investigator 1 | Genmab U.S., Inc. | $6,220.80 | 12/03/2025 | Non-covered Recipient Entity START MIDWEST LLC | A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1235935648 |
| Principal investigator 1 | PFIZER INC. | $1,622.52 | 12/02/2025 | Non-covered Recipient Entity START Midwest START Midwest | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228707195 |
| Principal investigator 1 | ModernaTX, Inc. | $10,180.35 | 12/01/2025 | Non-covered Recipient Entity SOUTH TEXAS ACCELERATED | A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors | No dispute reported | 06/30/2026 | 1252984908 |
| Principal investigator 1 | ABBVIE INC. | $445.50 | 11/28/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202526038 |
| Principal investigator 1 | ABBVIE INC. | $445.50 | 11/28/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202526040 |
| Principal investigator 1 | ABBVIE INC. | $2,250.45 | 11/28/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202526042 |
| Principal investigator 1 | ABBVIE INC. | $87.75 | 11/28/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202526044 |
| Principal investigator 1 | ABBVIE INC. | $2,250.45 | 11/28/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202526046 |
| Principal investigator 1 | ABBVIE INC. | $87.75 | 11/28/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202526048 |
| Principal investigator 1 | ABBVIE INC. | $445.50 | 11/28/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202526072 |
| Principal investigator 1 | ABBVIE INC. | $472.50 | 11/27/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202525798 |
| Principal investigator 1 | ABBVIE INC. | $64.26 | 11/27/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202525802 |
| Principal investigator 1 | ABBVIE INC. | $3,500.01 | 11/27/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202525804 |
| Principal investigator 1 | ABBVIE INC. | $32.13 | 11/27/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202525806 |
| Principal investigator 1 | ABBVIE INC. | $32.13 | 11/27/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202525808 |
| Principal investigator 1 | ABBVIE INC. | $7,425.00 | 11/27/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202525810 |
| Principal investigator 1 | ABBVIE INC. | $472.50 | 11/27/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202525812 |
| Principal investigator 1 | ABBVIE INC. | $3,253.50 | 11/27/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202525824 |
| Principal investigator 1 | ABBVIE INC. | $3,152.25 | 11/27/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202525826 |
| Principal investigator 1 | ABBVIE INC. | $2,813.27 | 11/27/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202525828 |
| Principal investigator 1 | ABBVIE INC. | $3,253.50 | 11/27/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202525830 |
| Principal investigator 1 | ABBVIE INC. | $3,253.50 | 11/27/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202525832 |
| Principal investigator 1 | ABBVIE INC. | $3,152.25 | 11/27/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202525834 |
| Principal investigator 1 | ABBVIE INC. | $135.00 | 11/27/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202525838 |
| Principal investigator 1 | ABBVIE INC. | $67.50 | 11/27/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202525840 |
| Principal investigator 1 | ABBVIE INC. | $490.05 | 11/27/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202525842 |
| Principal investigator 1 | ABBVIE INC. | $7,425.00 | 11/27/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202525844 |
| Principal investigator 1 | ABBVIE INC. | $3,711.15 | 11/27/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202525846 |
| Principal investigator 1 | ABBVIE INC. | $67.50 | 11/27/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202525848 |
| Principal investigator 1 | ABBVIE INC. | $32.13 | 11/27/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202525850 |
| Principal investigator 1 | ABBVIE INC. | $4,478.56 | 11/27/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202525852 |
| Principal investigator 1 | ABBVIE INC. | $54.00 | 11/27/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202525854 |
| Principal investigator 1 | ABBVIE INC. | $67.50 | 11/27/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202525856 |
| Principal investigator 1 | ABBVIE INC. | $3,152.25 | 11/27/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202525862 |
| Principal investigator 1 | ABBVIE INC. | $135.00 | 11/27/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202525864 |
| Principal investigator 1 | ABBVIE INC. | $229.50 | 11/27/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202525866 |
| Principal investigator 1 | ABBVIE INC. | $67.50 | 11/27/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202525868 |
| Principal investigator 1 | ABBVIE INC. | $365.85 | 11/27/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202525870 |
| Principal investigator 1 | ABBVIE INC. | $472.50 | 11/27/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202525872 |
| Principal investigator 1 | ABBVIE INC. | $101.25 | 11/27/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202525886 |
| Principal investigator 1 | ABBVIE INC. | $101.25 | 11/27/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202525888 |
| Principal investigator 1 | ABBVIE INC. | $67.50 | 11/27/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202525892 |
| Principal investigator 1 | ABBVIE INC. | $67.50 | 11/27/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202525894 |
| Principal investigator 1 | ABBVIE INC. | $202.50 | 11/27/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202525904 |
| Principal investigator 1 | ABBVIE INC. | $101.25 | 11/27/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202525906 |
| Principal investigator 1 | ABBVIE INC. | $229.50 | 11/27/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202525908 |
| Principal investigator 1 | ABBVIE INC. | $367.00 | 11/27/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202525910 |
| Principal investigator 1 | ABBVIE INC. | $409.05 | 11/27/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202526002 |
| Principal investigator 1 | ABBVIE INC. | $7,425.00 | 11/27/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202526004 |
| Principal investigator 1 | ABBVIE INC. | $67.50 | 11/27/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202526006 |
| Principal investigator 1 | ABBVIE INC. | $75.60 | 11/26/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202525412 |
| Principal investigator 1 | ABBVIE INC. | $75.60 | 11/26/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202525418 |
| Principal investigator 1 | ABBVIE INC. | $75.60 | 11/26/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202525420 |
| Principal investigator 1 | ABBVIE INC. | $75.60 | 11/26/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202525422 |
| Principal investigator 1 | ABBVIE INC. | $75.60 | 11/26/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202525424 |
| Principal investigator 1 | ABBVIE INC. | $75.60 | 11/26/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202525426 |
| Principal investigator 1 | PFIZER INC. | $11,715.30 | 11/26/2025 | Non-covered Recipient Entity START Midwest LLC | AN OPENLABEL PHASE 1 STUDY TO EVALUATE PF08046037 AS MONOTHERAPY AND PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED MALIGNANCIES | No dispute reported | 06/30/2026 | 1228818493 |
| Principal investigator 1 | PFIZER INC. | $6,696.00 | 11/26/2025 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTITUMOR ACTIVITY OF PF07921585 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228818537 |
| Principal investigator 1 | Genmab U.S., Inc. | $719.89 | 11/24/2025 | Non-covered Recipient Entity SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS | First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235935319 |
| Principal investigator 1 | PFIZER INC. | $1,053.00 | 11/15/2025 | Non-covered Recipient Entity START Midwest LLC | AN OPENLABEL PHASE 1 STUDY TO EVALUATE PF08046037 AS MONOTHERAPY AND PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED MALIGNANCIES | No dispute reported | 06/30/2026 | 1228818489 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $46,500.00 | 11/14/2025 | Non-covered Recipient Entity START MIDWEST, LLC | A Phase I II Open label Dose Escalation and Expansion Study to Evaluate the Safety Pharmacokinetics Pharmacodynamics and Efficacy of AZD6750 a CD8 Guided IL2 Agent Alone and in Combination With Other Anticancer Agents in Participants with Select Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1185541746 |
| Principal investigator 1 | PFIZER INC. | $1,206.31 | 11/14/2025 | Non-covered Recipient Entity START Midwest LLC | PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY | No dispute reported | 06/30/2026 | 1228817910 |
| Principal investigator 1 | PFIZER INC. | $7,836.75 | 11/14/2025 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1 OPENLABEL STUDY OF PF07934040 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS HARBORING MUTATIONS IN THE KRAS GENE | No dispute reported | 06/30/2026 | 1228817959 |
| Principal investigator 1 | PFIZER INC. | $6,090.22 | 11/14/2025 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228818481 |
| Principal investigator 1 | Tanabe Pharma America, Inc. | $14,521.35 | 11/14/2025 | Non-covered Recipient Entity START Midwest, LLC | A Phase I/II, Dose-escalation and Dose-optimization Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy ofMT-4561in Patients With Various Advanced Solid Tumors and to Evaluate Effect ofMT-4561on Pharmacokinetics of Oral Midazolam | No dispute reported | 06/30/2026 | 1243870901 |
| Principal investigator 1 | ABBVIE INC. | $55,370.25 | 11/13/2025 | Non-covered Recipient Entity START MIDWEST LLC | A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1202524337 |
| Principal investigator 1 | Genmab U.S., Inc. | $825.00 | 11/12/2025 | Non-covered Recipient Entity START MIDWEST LLC | A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1235935546 |
| Principal investigator 1 | Genmab U.S., Inc. | $19,656.01 | 11/12/2025 | Non-covered Recipient Entity START MIDWEST LLC | A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1235935615 |
| Principal investigator 1 | Genmab U.S., Inc. | $1,925.00 | 11/12/2025 | Non-covered Recipient Entity START MIDWEST LLC | A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1235935622 |
| Principal investigator 1 | ModernaTX, Inc. | $16,166.27 | 11/12/2025 | Non-covered Recipient Entity SOUTH TEXAS ACCELERATED | A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors | No dispute reported | 06/30/2026 | 1252984902 |
| Principal investigator 1 | ModernaTX, Inc. | $350.00 | 11/12/2025 | Non-covered Recipient Entity SOUTH TEXAS ACCELERATED | A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors | No dispute reported | 06/30/2026 | 1252984906 |
| Principal investigator 1 | ABBVIE INC. | $550.00 | 11/06/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202523171 |
| Principal investigator 1 | ABBVIE INC. | $630.00 | 11/06/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202523177 |
| Principal investigator 1 | ABBVIE INC. | $1,998.00 | 11/05/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202521267 |
| Principal investigator 1 | ABBVIE INC. | $270.00 | 11/05/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202521273 |
| Principal investigator 1 | ABBVIE INC. | $2,338.20 | 11/05/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202521275 |
| Principal investigator 1 | ABBVIE INC. | $1,788.75 | 11/05/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202521277 |
| Principal investigator 1 | ABBVIE INC. | $2,338.20 | 11/05/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202521279 |
| Principal investigator 1 | ABBVIE INC. | $270.00 | 11/05/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202521281 |
| Principal investigator 1 | ABBVIE INC. | $2,338.20 | 11/05/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202521287 |
| Principal investigator 1 | ABBVIE INC. | $270.00 | 11/05/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202521289 |
| Principal investigator 1 | ABBVIE INC. | $270.00 | 11/05/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202521291 |
| Principal investigator 1 | ABBVIE INC. | $270.00 | 11/05/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202521297 |
| Principal investigator 1 | ABBVIE INC. | $1,998.00 | 11/05/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202521299 |
| Principal investigator 1 | ABBVIE INC. | $270.00 | 11/05/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202521301 |
| Principal investigator 1 | ABBVIE INC. | $1,788.75 | 11/05/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202521305 |
| Principal investigator 1 | ABBVIE INC. | $270.00 | 11/05/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202521307 |
| Principal investigator 1 | ABBVIE INC. | $1,788.75 | 11/05/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202521311 |
| Principal investigator 1 | ABBVIE INC. | $5,817.15 | 11/05/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202521313 |
| Principal investigator 1 | ABBVIE INC. | $270.00 | 11/05/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202521315 |
| Principal investigator 1 | ABBVIE INC. | $1,998.00 | 11/05/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202521317 |
| Principal investigator 1 | ABBVIE INC. | $270.00 | 11/05/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202521319 |
| Principal investigator 1 | PFIZER INC. | $3,393.13 | 11/05/2025 | Non-covered Recipient Entity START Midwest LLC | A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228817905 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $48,880.00 | 11/04/2025 | Non-covered Recipient Entity START Midwest, LLC | An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of INBRX 106 and INBRX-106 in Combination with Pembrolizumab in Subjects with Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1232931800 |
| Principal investigator 1 | PFIZER INC. | $40,531.05 | 11/04/2025 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1 OPENLABEL STUDY OF PF07934040 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS HARBORING MUTATIONS IN THE KRAS GENE | No dispute reported | 06/30/2026 | 1228817965 |
| Principal investigator 1 | PFIZER INC. | $6,265.00 | 11/04/2025 | Non-covered Recipient Entity START Midwest LLC | AN OPENLABEL PHASE 1 STUDY TO EVALUATE PF08046037 AS MONOTHERAPY AND PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED MALIGNANCIES | No dispute reported | 06/30/2026 | 1228818438 |
| Principal investigator 1 | PFIZER INC. | $25,886.20 | 11/04/2025 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTITUMOR ACTIVITY OF PF07921585 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228818531 |
| Principal investigator 1 | PFIZER INC. | $1,622.52 | 11/03/2025 | Non-covered Recipient Entity START Midwest START Midwest | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228715201 |
| Principal investigator 1 | ABBVIE INC. | $1,456.65 | 10/29/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202518899 |
| Principal investigator 1 | ABBVIE INC. | $1,456.65 | 10/29/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202518955 |
| Principal investigator 1 | ABBVIE INC. | $1,456.65 | 10/29/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202519005 |
| Principal investigator 1 | ABBVIE INC. | $2,060.10 | 10/29/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202519041 |
| Principal investigator 1 | ABBVIE INC. | $2,060.10 | 10/29/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202519043 |
| Principal investigator 1 | ABBVIE INC. | $2,060.10 | 10/29/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202519119 |
| Principal investigator 1 | ABBVIE INC. | $1,456.65 | 10/29/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202519319 |
| Principal investigator 1 | ABBVIE INC. | $1,456.65 | 10/29/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202519355 |
| Principal investigator 1 | ABBVIE INC. | $3,152.25 | 10/29/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202519357 |
| Principal investigator 1 | ABBVIE INC. | $2,060.10 | 10/29/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202519411 |
| Principal investigator 1 | ABBVIE INC. | $1,456.65 | 10/29/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202519449 |
| Principal investigator 1 | ABBVIE INC. | $2,060.10 | 10/29/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202519455 |
| Principal investigator 1 | ABBVIE INC. | $2,060.10 | 10/29/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202519471 |
| Principal investigator 1 | ABBVIE INC. | $3,152.25 | 10/29/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202519481 |
| Principal investigator 1 | ABBVIE INC. | $364.50 | 10/27/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202518497 |
| Principal investigator 1 | ABBVIE INC. | $364.50 | 10/27/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202518501 |
| Principal investigator 1 | ABBVIE INC. | $229.50 | 10/27/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202518503 |
| Principal investigator 1 | ABBVIE INC. | $351.21 | 10/27/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202518581 |
| Principal investigator 1 | ABBVIE INC. | $244.35 | 10/27/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202518649 |
| Principal investigator 1 | Genmab U.S., Inc. | $719.89 | 10/23/2025 | Non-covered Recipient Entity SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS | First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235935311 |
| Principal investigator 1 | Genmab U.S., Inc. | $25,034.40 | 10/23/2025 | Non-covered Recipient Entity START MIDWEST LLC | A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1235935568 |
| Principal investigator 1 | Genmab U.S., Inc. | $7,250.85 | 10/23/2025 | Non-covered Recipient Entity START MIDWEST LLC | A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1235935592 |
| Principal investigator 1 | Genmab U.S., Inc. | $12,517.20 | 10/23/2025 | Non-covered Recipient Entity START MIDWEST LLC | A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1235935611 |
| Principal investigator 1 | ABBVIE INC. | $2,250.45 | 10/22/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517733 |
| Principal investigator 1 | ABBVIE INC. | $2,351.70 | 10/22/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517735 |
| Principal investigator 1 | ABBVIE INC. | $1,776.60 | 10/22/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517745 |
| Principal investigator 1 | ABBVIE INC. | $2,351.70 | 10/22/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517747 |
| Principal investigator 1 | ABBVIE INC. | $3,354.75 | 10/22/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517749 |
| Principal investigator 1 | ABBVIE INC. | $3,354.75 | 10/22/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517751 |
| Principal investigator 1 | ABBVIE INC. | $2,250.45 | 10/22/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517765 |
| Principal investigator 1 | ABBVIE INC. | $2,250.45 | 10/22/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517789 |
| Principal investigator 1 | ABBVIE INC. | $2,351.70 | 10/22/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517809 |
| Principal investigator 1 | ABBVIE INC. | $3,354.75 | 10/22/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517819 |
| Principal investigator 1 | ABBVIE INC. | $1,776.60 | 10/22/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517827 |
| Principal investigator 1 | ABBVIE INC. | $1,776.60 | 10/22/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517841 |
| Principal investigator 1 | ABBVIE INC. | $2,351.70 | 10/22/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517843 |
| Principal investigator 1 | ABBVIE INC. | $3,354.75 | 10/22/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517987 |
| Principal investigator 1 | ABBVIE INC. | $3,354.75 | 10/22/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517989 |
| Principal investigator 1 | ABBVIE INC. | $2,351.70 | 10/22/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517991 |
| Principal investigator 1 | ABBVIE INC. | $1,776.60 | 10/22/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202518015 |
| Principal investigator 1 | ABBVIE INC. | $2,250.45 | 10/22/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202518017 |
| Principal investigator 1 | ABBVIE INC. | $2,351.70 | 10/22/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202518019 |
| Principal investigator 1 | ABBVIE INC. | $3,354.75 | 10/22/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202518021 |
| Principal investigator 1 | ABBVIE INC. | $1,776.60 | 10/22/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202518031 |
| Principal investigator 1 | PFIZER INC. | $584.55 | 10/16/2025 | Non-covered Recipient Entity START Midwest LLC | AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B2 OPENLABEL STUDY TO INVESTIGATE TOLERABILITY PK AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT ARV471PF07850327 AN ORAL PROTEOLYSIS TARGETING CHIMERA IN COMBINATION WITH PF07220060 IN PARTICIPANTS AGED 18 YEARS AND OLDER WITH ERHER2 ADVANCED OR METASTATIC BREAST CANCER | No dispute reported | 06/30/2026 | 1228825227 |
| Principal investigator 1 | ABBVIE INC. | $62,492.85 | 10/15/2025 | Non-covered Recipient Entity START MIDWEST LLC | A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1202517071 |
| Principal investigator 1 | ModernaTX, Inc. | $12,028.51 | 10/15/2025 | Non-covered Recipient Entity SOUTH TEXAS ACCELERATED | A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors | No dispute reported | 06/30/2026 | 1252984910 |
| Principal investigator 1 | PFIZER INC. | $4,642.42 | 10/15/2025 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228825480 |
| Principal investigator 1 | PFIZER INC. | $6,912.00 | 10/15/2025 | Non-covered Recipient Entity START Midwest LLC | AN OPENLABEL PHASE 1 STUDY TO EVALUATE PF08046037 AS MONOTHERAPY AND PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED MALIGNANCIES | No dispute reported | 06/30/2026 | 1228826143 |
| Principal investigator 1 | Tanabe Pharma America, Inc. | $50,535.90 | 10/15/2025 | Non-covered Recipient Entity START Midwest, LLC | A Phase I/II, Dose-escalation and Dose-optimization Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy ofMT-4561in Patients With Various Advanced Solid Tumors and to Evaluate Effect ofMT-4561on Pharmacokinetics of Oral Midazolam | No dispute reported | 06/30/2026 | 1243870899 |
| Principal investigator 1 | ABBVIE INC. | $2,274.67 | 10/13/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202516589 |
| Principal investigator 1 | ABBVIE INC. | $500.00 | 10/13/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202516591 |
| Principal investigator 1 | ABBVIE INC. | $609.00 | 10/09/2025 | Non-covered Recipient Entity START MIDWEST LLC | A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1202516491 |
| Principal investigator 1 | PFIZER INC. | $10,352.41 | 10/09/2025 | Non-covered Recipient Entity START Midwest LLC | A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228826071 |
| Principal investigator 1 | PFIZER INC. | $5,800.00 | 10/08/2025 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07820435 AS MONOTHERAPY AND IN COMBINATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228824361 |
| Principal investigator 1 | PFIZER INC. | $1,622.52 | 10/06/2025 | Non-covered Recipient Entity START Midwest START Midwest | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228715203 |
| Principal investigator 1 | ABBVIE INC. | $2,813.27 | 09/29/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202512572 |
| Principal investigator 1 | ABBVIE INC. | $4,657.50 | 09/29/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202512598 |
| Principal investigator 1 | ABBVIE INC. | $364.50 | 09/29/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202512610 |
| Principal investigator 1 | ABBVIE INC. | $4,657.50 | 09/29/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202512708 |
| Principal investigator 1 | ABBVIE INC. | $30,551.85 | 09/26/2025 | Non-covered Recipient Entity START MIDWEST LLC | A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1202512540 |
| Principal investigator 1 | PFIZER INC. | $65.00 | 09/26/2025 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTITUMOR ACTIVITY OF PF07921585 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228836335 |
| Principal investigator 1 | ABBVIE INC. | $2,274.67 | 09/24/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202511974 |
| Principal investigator 1 | ABBVIE INC. | $1,684.94 | 09/24/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202512042 |
| Principal investigator 1 | ABBVIE INC. | $2,274.67 | 09/24/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202512044 |
| Principal investigator 1 | ABBVIE INC. | $2,274.67 | 09/24/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202512046 |
| Principal investigator 1 | PFIZER INC. | $3,545.00 | 09/24/2025 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07820435 AS MONOTHERAPY AND IN COMBINATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228835341 |
| Principal investigator 1 | PFIZER INC. | $13,293.22 | 09/24/2025 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228836706 |
| Principal investigator 1 | Genmab U.S., Inc. | $385.00 | 09/23/2025 | Non-covered Recipient Entity START MIDWEST LLC | A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1235935492 |
| Principal investigator 1 | ModernaTX, Inc. | $4,241.03 | 09/19/2025 | Non-covered Recipient Entity SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS LLC | A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors | No dispute reported | 06/30/2026 | 1252984914 |
| Principal investigator 1 | PFIZER INC. | $15.00 | 09/19/2025 | Non-covered Recipient Entity START Midwest | A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228714038 |
| Principal investigator 1 | ABBVIE INC. | $500.00 | 09/17/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202511140 |
| Principal investigator 1 | Stemline Therapeutics Inc. | $10,577.25 | 09/17/2025 | Non-covered Recipient Entity START MIDWEST, LLC | A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer | No dispute reported | 06/30/2026 | 1244134800 |
| Principal investigator 1 | Stemline Therapeutics Inc. | $715.50 | 09/17/2025 | Non-covered Recipient Entity START MIDWEST, LLC | A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer | No dispute reported | 06/30/2026 | 1244134803 |
| Principal investigator 1 | ABBVIE INC. | $3,680.10 | 09/16/2025 | Non-covered Recipient Entity START MIDWEST LLC | A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1202511118 |
| Principal investigator 1 | PFIZER INC. | $4,406.41 | 09/16/2025 | Non-covered Recipient Entity START Midwest LLC | A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228836317 |
| Principal investigator 1 | PFIZER INC. | $4,184.33 | 09/16/2025 | Non-covered Recipient Entity START Midwest LLC | AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B2 OPENLABEL STUDY TO INVESTIGATE TOLERABILITY PK AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT ARV471PF07850327 AN ORAL PROTEOLYSIS TARGETING CHIMERA IN COMBINATION WITH PF07220060 IN PARTICIPANTS AGED 18 YEARS AND OLDER WITH ERHER2 ADVANCED OR METASTATIC BREAST CANCER | No dispute reported | 06/30/2026 | 1228836817 |
| Principal investigator 1 | PFIZER INC. | $12,638.65 | 09/16/2025 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTITUMOR ACTIVITY OF PF07921585 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228836891 |
| Principal investigator 1 | ABBVIE INC. | $790.00 | 09/15/2025 | Non-covered Recipient Entity START MIDWEST LLC | A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202510946 |
| Principal investigator 1 | Genmab U.S., Inc. | $4,403.70 | 09/15/2025 | Non-covered Recipient Entity START MIDWEST LLC | A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1235935510 |
| Principal investigator 1 | Tanabe Pharma America, Inc. | $139,771.72 | 09/15/2025 | Non-covered Recipient Entity START Midwest, LLC | A Phase I/II, Dose-escalation and Dose-optimization Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy ofMT-4561in Patients With Various Advanced Solid Tumors and to Evaluate Effect ofMT-4561on Pharmacokinetics of Oral Midazolam | No dispute reported | 06/30/2026 | 1243870897 |
| Principal investigator 1 | ABBVIE INC. | $30,138.75 | 09/12/2025 | Non-covered Recipient Entity START MIDWEST LLC | A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1202510866 |
| Principal investigator 1 | ABBVIE INC. | $12,958.65 | 09/12/2025 | Non-covered Recipient Entity START MIDWEST LLC | A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1202510868 |
| Principal investigator 1 | Genmab U.S., Inc. | $12,517.20 | 09/09/2025 | Non-covered Recipient Entity START MIDWEST LLC | A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1235935506 |
| Principal investigator 1 | PFIZER INC. | $1,857.60 | 09/09/2025 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1 OPENLABEL STUDY OF PF07934040 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS HARBORING MUTATIONS IN THE KRAS GENE | No dispute reported | 06/30/2026 | 1228835295 |
| Principal investigator 1 | Genmab U.S., Inc. | $4,504.95 | 09/08/2025 | Non-covered Recipient Entity START MIDWEST LLC | A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1235935480 |
| Principal investigator 1 | PFIZER INC. | $1,622.52 | 09/08/2025 | Non-covered Recipient Entity START Midwest START Midwest | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228714831 |
| Principal investigator 1 | ABBVIE INC. | $1,020.00 | 09/05/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202510144 |
| Principal investigator 1 | PFIZER INC. | $6,583.95 | 09/03/2025 | Non-covered Recipient Entity START Midwest LLC | AN OPENLABEL PHASE 1 STUDY TO EVALUATE PF08046037 AS MONOTHERAPY AND PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED MALIGNANCIES | No dispute reported | 06/30/2026 | 1228836713 |
| Principal investigator 1 | ABBVIE INC. | $21,100.00 | 09/02/2025 | Non-covered Recipient Entity START MIDWEST LLC | A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1202507023 |
| Principal investigator 1 | ABBVIE INC. | $2,250.45 | 09/01/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506579 |
| Principal investigator 1 | ABBVIE INC. | $4,657.50 | 09/01/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506581 |
| Principal investigator 1 | ABBVIE INC. | $2,250.45 | 09/01/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506583 |
| Principal investigator 1 | ABBVIE INC. | $522.18 | 09/01/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506585 |
| Principal investigator 1 | ABBVIE INC. | $457.89 | 09/01/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506587 |
| Principal investigator 1 | ABBVIE INC. | $159.37 | 09/01/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506589 |
| Principal investigator 1 | ABBVIE INC. | $98.62 | 09/01/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506591 |
| Principal investigator 1 | ABBVIE INC. | $2,408.27 | 09/01/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506593 |
| Principal investigator 1 | ABBVIE INC. | $128.25 | 09/01/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506595 |
| Principal investigator 1 | ABBVIE INC. | $2,813.27 | 09/01/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506609 |
| Principal investigator 1 | ABBVIE INC. | $986.71 | 09/01/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506611 |
| Principal investigator 1 | ABBVIE INC. | $2,408.27 | 09/01/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506613 |
| Principal investigator 1 | ABBVIE INC. | $55.35 | 09/01/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506623 |
| Principal investigator 1 | ABBVIE INC. | $4,233.60 | 09/01/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506625 |
| Principal investigator 1 | ABBVIE INC. | $98.62 | 09/01/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506627 |
| Principal investigator 1 | ABBVIE INC. | $98.62 | 09/01/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506629 |
| Principal investigator 1 | ABBVIE INC. | $140.40 | 09/01/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506631 |
| Principal investigator 1 | ABBVIE INC. | $162.21 | 09/01/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506633 |
| Principal investigator 1 | ABBVIE INC. | $67.71 | 09/01/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506635 |
| Principal investigator 1 | ABBVIE INC. | $2,408.27 | 09/01/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506637 |
| Principal investigator 1 | ABBVIE INC. | $4,657.50 | 09/01/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506659 |
| Principal investigator 1 | ABBVIE INC. | $4,233.60 | 09/01/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506661 |
| Principal investigator 1 | ABBVIE INC. | $1,544.40 | 09/01/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506663 |
| Principal investigator 1 | ABBVIE INC. | $3,253.50 | 09/01/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506665 |
| Principal investigator 1 | ABBVIE INC. | $140.40 | 09/01/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506667 |
| Principal investigator 1 | ABBVIE INC. | $140.40 | 09/01/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506679 |
| Principal investigator 1 | ABBVIE INC. | $519.08 | 09/01/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506681 |
| Principal investigator 1 | ABBVIE INC. | $364.50 | 09/01/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506683 |
| Principal investigator 1 | ABBVIE INC. | $140.40 | 09/01/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506699 |
| Principal investigator 1 | ABBVIE INC. | $162.21 | 09/01/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506701 |
| Principal investigator 1 | ABBVIE INC. | $1,080.21 | 09/01/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506703 |
| Principal investigator 1 | ABBVIE INC. | $72.00 | 09/01/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506705 |
| Principal investigator 1 | ABBVIE INC. | $128.25 | 09/01/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506707 |
| Principal investigator 1 | ABBVIE INC. | $98.62 | 09/01/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506709 |
| Principal investigator 1 | ABBVIE INC. | $140.40 | 09/01/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506713 |
| Principal investigator 1 | ABBVIE INC. | $162.21 | 09/01/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506715 |
| Principal investigator 1 | ABBVIE INC. | $159.37 | 09/01/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506717 |
| Principal investigator 1 | ABBVIE INC. | $1,544.40 | 09/01/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506719 |
| Principal investigator 1 | ABBVIE INC. | $128.25 | 09/01/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506721 |
| Principal investigator 1 | ABBVIE INC. | $696.60 | 09/01/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506723 |
| Principal investigator 1 | ABBVIE INC. | $67.71 | 09/01/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506725 |
| Principal investigator 1 | ABBVIE INC. | $229.50 | 09/01/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506805 |
| Principal investigator 1 | ABBVIE INC. | $67.71 | 09/01/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506807 |
| Principal investigator 1 | ABBVIE INC. | $472.71 | 09/01/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506809 |
| Principal investigator 1 | ABBVIE INC. | $472.71 | 09/01/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506811 |
| Principal investigator 1 | ABBVIE INC. | $4,657.50 | 09/01/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506813 |
| Principal investigator 1 | ABBVIE INC. | $2,408.27 | 09/01/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506815 |
| Principal investigator 1 | ABBVIE INC. | $499.50 | 09/01/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506833 |
| Principal investigator 1 | ABBVIE INC. | $128.25 | 09/01/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506835 |
| Principal investigator 1 | ABBVIE INC. | $457.89 | 09/01/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506837 |
| Principal investigator 1 | ABBVIE INC. | $4,657.50 | 09/01/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506839 |
| Principal investigator 1 | ABBVIE INC. | $67.71 | 09/01/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506843 |
| Principal investigator 1 | ABBVIE INC. | $2,813.27 | 09/01/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506845 |
| Principal investigator 1 | ABBVIE INC. | $1,544.40 | 09/01/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506861 |
| Principal investigator 1 | ABBVIE INC. | $4,233.60 | 09/01/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506863 |
| Principal investigator 1 | ABBVIE INC. | $1,544.40 | 09/01/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506865 |
| Principal investigator 1 | ABBVIE INC. | $1,544.40 | 09/01/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506867 |
| Principal investigator 1 | ABBVIE INC. | $140.40 | 09/01/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506869 |
| Principal investigator 1 | ABBVIE INC. | $98.62 | 09/01/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506871 |
| Principal investigator 1 | ABBVIE INC. | $1,544.40 | 09/01/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506873 |
| Principal investigator 1 | ABBVIE INC. | $4,233.60 | 09/01/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506875 |
| Principal investigator 1 | ABBVIE INC. | $4,233.60 | 09/01/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506877 |
| Principal investigator 1 | ABBVIE INC. | $4,233.60 | 09/01/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506879 |
| Principal investigator 1 | ABBVIE INC. | $1,764.00 | 08/31/2025 | Non-covered Recipient Entity START MIDWEST LLC | A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1202506577 |
| Principal investigator 1 | ABBVIE INC. | $13,230.00 | 08/29/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506531 |
| Principal investigator 1 | ABBVIE INC. | $710.00 | 08/29/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506533 |
| Principal investigator 1 | ABBVIE INC. | $1,788.75 | 08/29/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506535 |
| Principal investigator 1 | ABBVIE INC. | $5,817.15 | 08/29/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506537 |
| Principal investigator 1 | ABBVIE INC. | $2,338.20 | 08/29/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506539 |
| Principal investigator 1 | ABBVIE INC. | $934.20 | 08/29/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506569 |
| Principal investigator 1 | ABBVIE INC. | $1,998.00 | 08/29/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506571 |
| Principal investigator 1 | ABBVIE INC. | $1,788.75 | 08/28/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506275 |
| Principal investigator 1 | ABBVIE INC. | $270.00 | 08/28/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506277 |
| Principal investigator 1 | ABBVIE INC. | $270.00 | 08/28/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506279 |
| Principal investigator 1 | ABBVIE INC. | $1,998.00 | 08/28/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506291 |
| Principal investigator 1 | ABBVIE INC. | $270.00 | 08/28/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506303 |
| Principal investigator 1 | ABBVIE INC. | $270.00 | 08/28/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506305 |
| Principal investigator 1 | ABBVIE INC. | $1,998.00 | 08/28/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506307 |
| Principal investigator 1 | ABBVIE INC. | $1,788.75 | 08/28/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506309 |
| Principal investigator 1 | ABBVIE INC. | $2,338.20 | 08/28/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506311 |
| Principal investigator 1 | ABBVIE INC. | $2,338.20 | 08/28/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506317 |
| Principal investigator 1 | ABBVIE INC. | $270.00 | 08/28/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506489 |
| Principal investigator 1 | ABBVIE INC. | $270.00 | 08/28/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506495 |
| Principal investigator 1 | Ipsen Pharma SAS | $5,575.50 | 08/28/2025 | Non-covered Recipient Entity Cancer And Hematology Centers Of Western Michigan, Pc | An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184304921 |
| Principal investigator 1 | PFIZER INC. | $61,551.91 | 08/27/2025 | Non-covered Recipient Entity START Midwest LLC | AN OPENLABEL PHASE 1 STUDY TO EVALUATE PF08046037 AS MONOTHERAPY AND PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED MALIGNANCIES | No dispute reported | 06/30/2026 | 1228841313 |
| Principal investigator 1 | PFIZER INC. | $191.03 | 08/23/2025 | Non-covered Recipient Entity START Midwest LLC | AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B2 OPENLABEL STUDY TO INVESTIGATE TOLERABILITY PK AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT ARV471PF07850327 AN ORAL PROTEOLYSIS TARGETING CHIMERA IN COMBINATION WITH PF07220060 IN PARTICIPANTS AGED 18 YEARS AND OLDER WITH ERHER2 ADVANCED OR METASTATIC BREAST CANCER | No dispute reported | 06/30/2026 | 1228841283 |
| Principal investigator 1 | ABBVIE INC. | $4,233.60 | 08/22/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202505587 |
| Principal investigator 1 | ModernaTX, Inc. | $13,212.46 | 08/22/2025 | Non-covered Recipient Entity SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS LLC | A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors | No dispute reported | 06/30/2026 | 1252984912 |
| Principal investigator 1 | PFIZER INC. | $4,530.60 | 08/22/2025 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1 OPENLABEL STUDY OF PF07934040 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS HARBORING MUTATIONS IN THE KRAS GENE | No dispute reported | 06/30/2026 | 1228842644 |
| Principal investigator 1 | ABBVIE INC. | $80,493.71 | 08/20/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202505199 |
| Principal investigator 1 | Genmab U.S., Inc. | $5,723.19 | 08/18/2025 | Non-covered Recipient Entity START MIDWEST LLC | A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1235935502 |
| Principal investigator 1 | PFIZER INC. | $2,740.41 | 08/14/2025 | Non-covered Recipient Entity START Midwest LLC | A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228841319 |
| Principal investigator 1 | PFIZER INC. | $4,642.42 | 08/14/2025 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228841981 |
| Principal investigator 1 | Genmab U.S., Inc. | $4,163.40 | 08/11/2025 | Non-covered Recipient Entity START MIDWEST LLC | A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1235935467 |
| Principal investigator 1 | PFIZER INC. | $1,622.52 | 08/11/2025 | Non-covered Recipient Entity START Midwest START Midwest | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228707111 |
| Principal investigator 1 | ABBVIE INC. | $3,152.25 | 08/07/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202503725 |
| Principal investigator 1 | ABBVIE INC. | $3,152.25 | 08/07/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202503787 |
| Principal investigator 1 | ABBVIE INC. | $3,711.15 | 08/07/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202503789 |
| Principal investigator 1 | ABBVIE INC. | $3,152.25 | 08/07/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202503791 |
| Principal investigator 1 | ABBVIE INC. | $3,152.25 | 08/07/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202503989 |
| Principal investigator 1 | PFIZER INC. | $3,668.00 | 08/05/2025 | Non-covered Recipient Entity START Midwest LLC | AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B2 OPENLABEL STUDY TO INVESTIGATE TOLERABILITY PK AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT ARV471PF07850327 AN ORAL PROTEOLYSIS TARGETING CHIMERA IN COMBINATION WITH PF07220060 IN PARTICIPANTS AGED 18 YEARS AND OLDER WITH ERHER2 ADVANCED OR METASTATIC BREAST CANCER | No dispute reported | 06/30/2026 | 1228841307 |
| Principal investigator 1 | PFIZER INC. | $952.00 | 08/02/2025 | Non-covered Recipient Entity START Midwest LLC | PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY | No dispute reported | 06/30/2026 | 1228841393 |
| Principal investigator 1 | PFIZER INC. | $910.00 | 08/02/2025 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1 OPENLABEL STUDY OF PF07934040 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS HARBORING MUTATIONS IN THE KRAS GENE | No dispute reported | 06/30/2026 | 1228842637 |
| Principal investigator 1 | ABBVIE INC. | $440.00 | 08/01/2025 | Non-covered Recipient Entity START MIDWEST LLC | A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1202500894 |
| Principal investigator 1 | ABBVIE INC. | $365.85 | 07/28/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202499894 |
| Principal investigator 1 | Ipsen Pharma SAS | $10,233.00 | 07/28/2025 | Non-covered Recipient Entity Cancer And Hematology Centers Of Western Michigan, Pc | An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184304907 |
| Principal investigator 1 | Ipsen Pharma SAS | $5,136.75 | 07/28/2025 | Non-covered Recipient Entity Cancer And Hematology Centers Of Western Michigan, Pc | An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184304909 |
| Principal investigator 1 | Ipsen Pharma SAS | $6,582.60 | 07/28/2025 | Non-covered Recipient Entity Cancer And Hematology Centers Of Western Michigan, Pc | An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184304911 |
| Principal investigator 1 | Ipsen Pharma SAS | $6,660.90 | 07/28/2025 | Non-covered Recipient Entity Cancer And Hematology Centers Of Western Michigan, Pc | An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184304913 |
| Principal investigator 1 | Ipsen Pharma SAS | $10,233.00 | 07/28/2025 | Non-covered Recipient Entity Cancer And Hematology Centers Of Western Michigan, Pc | An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184304915 |
| Principal investigator 1 | Ipsen Pharma SAS | $5,136.75 | 07/28/2025 | Non-covered Recipient Entity Cancer And Hematology Centers Of Western Michigan, Pc | An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184304917 |
| Principal investigator 1 | Ipsen Pharma SAS | $6,582.60 | 07/28/2025 | Non-covered Recipient Entity Cancer And Hematology Centers Of Western Michigan, Pc | An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184304919 |
| Principal investigator 1 | PFIZER INC. | $7,375.05 | 07/26/2025 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1 OPENLABEL STUDY OF PF07934040 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS HARBORING MUTATIONS IN THE KRAS GENE | No dispute reported | 06/30/2026 | 1228844812 |
| Principal investigator 1 | PFIZER INC. | $65.00 | 07/25/2025 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTITUMOR ACTIVITY OF PF07921585 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228848534 |
| Principal investigator 1 | PFIZER INC. | $4,642.42 | 07/25/2025 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228848540 |
| Principal investigator 1 | ABBVIE INC. | $17,811.90 | 07/23/2025 | Non-covered Recipient Entity START MIDWEST LLC | A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1202499416 |
| Principal investigator 1 | PFIZER INC. | $45.00 | 07/22/2025 | Non-covered Recipient Entity START Midwest | A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228707025 |
| Principal investigator 1 | PFIZER INC. | $1,622.52 | 07/22/2025 | Non-covered Recipient Entity START Midwest | A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228707199 |
| Principal investigator 1 | ABBVIE INC. | $18,118.73 | 07/21/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202498978 |
| Principal investigator 1 | ABBVIE INC. | $20,393.40 | 07/21/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202498980 |
| Principal investigator 1 | ABBVIE INC. | $13,186.45 | 07/21/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202498994 |
| Principal investigator 1 | ABBVIE INC. | $12,453.59 | 07/21/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202498996 |
| Principal investigator 1 | Genmab U.S., Inc. | $5,723.19 | 07/21/2025 | Non-covered Recipient Entity START MIDWEST LLC | A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1235935471 |
| Principal investigator 1 | ABBVIE INC. | $2,058.75 | 07/18/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202498836 |
| Principal investigator 1 | ABBVIE INC. | $2,608.20 | 07/18/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202498838 |
| Principal investigator 1 | ABBVIE INC. | $6,007.50 | 07/18/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202498850 |
| Principal investigator 1 | ABBVIE INC. | $467.10 | 07/18/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202498854 |
| Principal investigator 1 | ABBVIE INC. | $2,268.00 | 07/18/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202498868 |
| Principal investigator 1 | ModernaTX, Inc. | $8,147.93 | 07/18/2025 | Non-covered Recipient Entity SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS LLC | A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors | No dispute reported | 06/30/2026 | 1252984916 |
| Principal investigator 1 | Stemline Therapeutics Inc. | $7,916.40 | 07/16/2025 | Non-covered Recipient Entity START MIDWEST, LLC | A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer | No dispute reported | 06/30/2026 | 1244134752 |
| Principal investigator 1 | Stemline Therapeutics Inc. | $14,037.30 | 07/16/2025 | Non-covered Recipient Entity START MIDWEST, LLC | A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer | No dispute reported | 06/30/2026 | 1244134757 |
| Principal investigator 1 | Stemline Therapeutics Inc. | $3,167.10 | 07/16/2025 | Non-covered Recipient Entity START MIDWEST, LLC | A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer | No dispute reported | 06/30/2026 | 1244134761 |
| Principal investigator 1 | Stemline Therapeutics Inc. | $4,869.45 | 07/16/2025 | Non-covered Recipient Entity START MIDWEST, LLC | A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer | No dispute reported | 06/30/2026 | 1244134765 |
| Principal investigator 1 | Stemline Therapeutics Inc. | $5,128.65 | 07/16/2025 | Non-covered Recipient Entity START MIDWEST, LLC | A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer | No dispute reported | 06/30/2026 | 1244134769 |
| Principal investigator 1 | Stemline Therapeutics Inc. | $5,751.00 | 07/16/2025 | Non-covered Recipient Entity START MIDWEST, LLC | A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer | No dispute reported | 06/30/2026 | 1244134773 |
| Principal investigator 1 | Stemline Therapeutics Inc. | $5,134.05 | 07/16/2025 | Non-covered Recipient Entity START MIDWEST, LLC | A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer | No dispute reported | 06/30/2026 | 1244134777 |
| Principal investigator 1 | Stemline Therapeutics Inc. | $1,502.55 | 07/16/2025 | Non-covered Recipient Entity START MIDWEST, LLC | A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer | No dispute reported | 06/30/2026 | 1244134780 |
| Principal investigator 1 | Stemline Therapeutics Inc. | $4,475.25 | 07/16/2025 | Non-covered Recipient Entity START MIDWEST, LLC | A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer | No dispute reported | 06/30/2026 | 1244134784 |
| Principal investigator 1 | Stemline Therapeutics Inc. | $4,637.25 | 07/16/2025 | Non-covered Recipient Entity START MIDWEST, LLC | A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer | No dispute reported | 06/30/2026 | 1244134788 |
| Principal investigator 1 | Stemline Therapeutics Inc. | $9,127.35 | 07/16/2025 | Non-covered Recipient Entity START MIDWEST, LLC | A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer | No dispute reported | 06/30/2026 | 1244134791 |
| Principal investigator 1 | Stemline Therapeutics Inc. | $3,026.70 | 07/16/2025 | Non-covered Recipient Entity START MIDWEST, LLC | A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer | No dispute reported | 06/30/2026 | 1244134796 |
| Principal investigator 1 | PFIZER INC. | $1,622.52 | 07/14/2025 | Non-covered Recipient Entity START Midwest START Midwest | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228707197 |
| Principal investigator 1 | PFIZER INC. | $28,992.60 | 07/11/2025 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1 OPENLABEL STUDY OF PF07934040 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS HARBORING MUTATIONS IN THE KRAS GENE | No dispute reported | 06/30/2026 | 1228844750 |
| Principal investigator 1 | PFIZER INC. | $2,618.00 | 07/11/2025 | Non-covered Recipient Entity START Midwest LLC | PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY | No dispute reported | 06/30/2026 | 1228848513 |
| Principal investigator 1 | ABBVIE INC. | $255.00 | 07/09/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202497528 |
| Principal investigator 1 | ABBVIE INC. | $500.00 | 07/04/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202496877 |
| Principal investigator 1 | ABBVIE INC. | $72,449.06 | 07/03/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202496743 |
| Principal investigator 1 | ABBVIE INC. | $16,638.75 | 07/02/2025 | Non-covered Recipient Entity START MIDWEST LLC | A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1202496735 |
| Principal investigator 1 | ABBVIE INC. | $38,534.40 | 07/01/2025 | Non-covered Recipient Entity START MIDWEST LLC | A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1202493887 |
| Principal investigator 1 | Genmab U.S., Inc. | $4,504.95 | 07/01/2025 | Non-covered Recipient Entity START MIDWEST LLC | A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1235935489 |
| Principal investigator 1 | PFIZER INC. | $1,996.65 | 07/01/2025 | Non-covered Recipient Entity START Midwest LLC | AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B2 OPENLABEL STUDY TO INVESTIGATE TOLERABILITY PK AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT ARV471PF07850327 AN ORAL PROTEOLYSIS TARGETING CHIMERA IN COMBINATION WITH PF07220060 IN PARTICIPANTS AGED 18 YEARS AND OLDER WITH ERHER2 ADVANCED OR METASTATIC BREAST CANCER | No dispute reported | 06/30/2026 | 1228848502 |
| Principal investigator 1 | ABBVIE INC. | $85,882.19 | 06/30/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202493655 |
| Principal investigator 1 | ABBVIE INC. | $65,664.36 | 06/30/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202493665 |
| Principal investigator 1 | ABBVIE INC. | $270.00 | 06/27/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202493425 |
| Principal investigator 1 | ABBVIE INC. | $270.00 | 06/27/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202493439 |
| Principal investigator 1 | ABBVIE INC. | $1,998.00 | 06/27/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202493441 |
| Principal investigator 1 | ABBVIE INC. | $3,152.25 | 06/27/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202493443 |
| Principal investigator 1 | ABBVIE INC. | $270.00 | 06/27/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202493447 |
| Principal investigator 1 | ABBVIE INC. | $3,711.15 | 06/27/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202493449 |
| Principal investigator 1 | ABBVIE INC. | $1,788.75 | 06/27/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202493451 |
| Principal investigator 1 | ABBVIE INC. | $2,338.20 | 06/27/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202493465 |
| Principal investigator 1 | ABBVIE INC. | $2,115.45 | 06/27/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202493467 |
| Principal investigator 1 | PFIZER INC. | $2,740.41 | 06/27/2025 | Non-covered Recipient Entity START Midwest LLC | A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228851460 |
| Principal investigator 1 | ABBVIE INC. | $2,813.27 | 06/26/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202492973 |
| Principal investigator 1 | ABBVIE INC. | $2,589.84 | 06/26/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202492999 |
| Principal investigator 1 | ABBVIE INC. | $2,157.84 | 06/26/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202493021 |
| Principal investigator 1 | ABBVIE INC. | $2,157.84 | 06/26/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202493025 |
| Principal investigator 1 | ABBVIE INC. | $2,813.27 | 06/26/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202493045 |
| Principal investigator 1 | PFIZER INC. | $4,642.42 | 06/26/2025 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228851452 |
| Principal investigator 1 | PFIZER INC. | $25,616.10 | 06/26/2025 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTITUMOR ACTIVITY OF PF07921585 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228851542 |
| Principal investigator 1 | Genmab U.S., Inc. | $55.00 | 06/24/2025 | Non-covered Recipient Entity SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS | First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235935092 |
| Principal investigator 1 | Genmab U.S., Inc. | $55.00 | 06/24/2025 | Non-covered Recipient Entity SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS | First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235935145 |
| Principal investigator 1 | PFIZER INC. | $15.00 | 06/23/2025 | Non-covered Recipient Entity START Midwest | A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228840173 |
| Principal investigator 1 | PFIZER INC. | $3,245.02 | 06/23/2025 | Non-covered Recipient Entity START Midwest | A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228840246 |
| Principal investigator 1 | Genmab U.S., Inc. | $190.00 | 06/20/2025 | Non-covered Recipient Entity START MIDWEST LLC | A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1235935476 |
| Principal investigator 1 | Genmab U.S., Inc. | $380.00 | 06/20/2025 | Non-covered Recipient Entity START MIDWEST LLC | A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1235935495 |
| Principal investigator 1 | ModernaTX, Inc. | $3,328.43 | 06/20/2025 | Non-covered Recipient Entity SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS LLC | A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors | No dispute reported | 06/30/2026 | 1252984918 |
| Principal investigator 1 | ABBVIE INC. | $50.00 | 06/18/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202491945 |
| Principal investigator 1 | ABBVIE INC. | $1,750.00 | 06/16/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202491523 |
| Principal investigator 1 | ABBVIE INC. | $250.00 | 06/16/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202491533 |
| Principal investigator 1 | ABBVIE INC. | $1,788.75 | 06/16/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202491539 |
| Principal investigator 1 | ABBVIE INC. | $270.00 | 06/16/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202491541 |
| Principal investigator 1 | ABBVIE INC. | $750.00 | 06/16/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202491579 |
| Principal investigator 1 | ABBVIE INC. | $5,817.15 | 06/16/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202491641 |
| Principal investigator 1 | ABBVIE INC. | $4,749.17 | 06/16/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202491645 |
| Principal investigator 1 | ABBVIE INC. | $270.00 | 06/16/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202491647 |
| Principal investigator 1 | ABBVIE INC. | $1,998.00 | 06/16/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202491649 |
| Principal investigator 1 | ABBVIE INC. | $500.00 | 06/16/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202491653 |
| Principal investigator 1 | ABBVIE INC. | $5,817.15 | 06/16/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202491655 |
| Principal investigator 1 | ABBVIE INC. | $825.00 | 06/16/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202491657 |
| Principal investigator 1 | ABBVIE INC. | $270.00 | 06/16/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202491661 |
| Principal investigator 1 | ABBVIE INC. | $2,338.20 | 06/16/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202491663 |
| Principal investigator 1 | PFIZER INC. | $1,622.51 | 06/16/2025 | Non-covered Recipient Entity START Midwest | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228840867 |
| Principal investigator 1 | ABBVIE INC. | $18,069.75 | 06/13/2025 | Non-covered Recipient Entity START MIDWEST LLC | A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1202491457 |
| Principal investigator 1 | Genmab U.S., Inc. | $450.00 | 06/13/2025 | Non-covered Recipient Entity SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS | First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235935102 |
| Principal investigator 1 | Genmab U.S., Inc. | $300.00 | 06/13/2025 | Non-covered Recipient Entity SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS | First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235935111 |
| Principal investigator 1 | Genmab U.S., Inc. | $200.00 | 06/13/2025 | Non-covered Recipient Entity SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS | First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235935114 |
| Principal investigator 1 | Genmab U.S., Inc. | $400.00 | 06/13/2025 | Non-covered Recipient Entity SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS | First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235935120 |
| Principal investigator 1 | Genmab U.S., Inc. | $150.00 | 06/13/2025 | Non-covered Recipient Entity SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS | First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235935127 |
| Principal investigator 1 | Genmab U.S., Inc. | $220.00 | 06/13/2025 | Non-covered Recipient Entity SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS | First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235935136 |
| Principal investigator 1 | Genmab U.S., Inc. | $400.00 | 06/13/2025 | Non-covered Recipient Entity SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS | First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235935140 |
| Principal investigator 1 | Genmab U.S., Inc. | $1,000.00 | 06/13/2025 | Non-covered Recipient Entity SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS | First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235935155 |
| Principal investigator 1 | Genmab U.S., Inc. | $4,163.40 | 06/09/2025 | Non-covered Recipient Entity START MIDWEST LLC | A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1235935484 |
| Principal investigator 1 | Genmab U.S., Inc. | $900.00 | 06/05/2025 | Non-covered Recipient Entity SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS | First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235935077 |
| Principal investigator 1 | Genmab U.S., Inc. | $650.00 | 06/05/2025 | Non-covered Recipient Entity SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS | First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235935081 |
| Principal investigator 1 | Genmab U.S., Inc. | $550.00 | 06/05/2025 | Non-covered Recipient Entity SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS | First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235935084 |
| Principal investigator 1 | Genmab U.S., Inc. | $600.00 | 06/05/2025 | Non-covered Recipient Entity SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS | First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235935088 |
| Principal investigator 1 | Genmab U.S., Inc. | $450.00 | 06/05/2025 | Non-covered Recipient Entity SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS | First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235935099 |
| Principal investigator 1 | Genmab U.S., Inc. | $400.00 | 06/05/2025 | Non-covered Recipient Entity SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS | First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235935106 |
| Principal investigator 1 | Genmab U.S., Inc. | $750.00 | 06/05/2025 | Non-covered Recipient Entity SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS | First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235935117 |
| Principal investigator 1 | Genmab U.S., Inc. | $200.00 | 06/05/2025 | Non-covered Recipient Entity SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS | First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235935124 |
| Principal investigator 1 | Genmab U.S., Inc. | $200.00 | 06/05/2025 | Non-covered Recipient Entity SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS | First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235935132 |
| Principal investigator 1 | ModernaTX, Inc. | $9,504.01 | 06/04/2025 | Non-covered Recipient Entity SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS LLC | A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors | No dispute reported | 06/30/2026 | 1252984898 |
| Principal investigator 1 | ModernaTX, Inc. | $2,992.95 | 06/04/2025 | Non-covered Recipient Entity SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS LLC | A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors | No dispute reported | 06/30/2026 | 1252984920 |
| Principal investigator 1 | ABBVIE INC. | $1,788.75 | 06/02/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202487177 |
| Principal investigator 1 | ABBVIE INC. | $1,277.10 | 06/02/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202487179 |
| Principal investigator 1 | ABBVIE INC. | $1,998.00 | 06/02/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202487195 |
| Principal investigator 1 | ABBVIE INC. | $1,080.00 | 06/02/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202487203 |
| Principal investigator 1 | ABBVIE INC. | $8,672.40 | 06/02/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202487219 |
| Principal investigator 1 | ABBVIE INC. | $6,007.50 | 06/02/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202487221 |
| Principal investigator 1 | ABBVIE INC. | $540.00 | 06/02/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202487235 |
| Principal investigator 1 | ABBVIE INC. | $1,788.75 | 06/02/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202487237 |
| Principal investigator 1 | ABBVIE INC. | $2,338.20 | 06/02/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202487241 |
| Principal investigator 1 | ABBVIE INC. | $26,345.51 | 06/02/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202487245 |
| Principal investigator 1 | ABBVIE INC. | $4,336.20 | 06/02/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202487247 |
| Principal investigator 1 | ABBVIE INC. | $1,788.75 | 06/02/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202487249 |
| Principal investigator 1 | ABBVIE INC. | $1,788.75 | 06/02/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202487251 |
| Principal investigator 1 | ModernaTX, Inc. | $47,490.00 | 06/02/2025 | Non-covered Recipient Entity SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS LLC | A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors | No dispute reported | 06/30/2026 | 1252984904 |
| Recipient | ABBVIE INC. | $43.20 | 05/30/2025 | Covered Recipient Physician | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202401317 |
| Principal investigator 1 | ABBVIE INC. | $3,000.00 | 05/30/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202487111 |
| Principal investigator 1 | PFIZER INC. | $1,965.00 | 05/30/2025 | Non-covered Recipient Entity START Midwest LLC | AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B2 OPENLABEL STUDY TO INVESTIGATE TOLERABILITY PK AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT ARV471PF07850327 AN ORAL PROTEOLYSIS TARGETING CHIMERA IN COMBINATION WITH PF07220060 IN PARTICIPANTS AGED 18 YEARS AND OLDER WITH ERHER2 ADVANCED OR METASTATIC BREAST CANCER | No dispute reported | 06/30/2026 | 1228855236 |
| Principal investigator 1 | PFIZER INC. | $15,089.23 | 05/30/2025 | Non-covered Recipient Entity START Midwest LLC | A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228855361 |
| Principal investigator 1 | PFIZER INC. | $40,683.00 | 05/30/2025 | Non-covered Recipient Entity START Midwest LLC | AN OPENLABEL PHASE 1 STUDY TO EVALUATE PF08046037 AS MONOTHERAPY AND PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED MALIGNANCIES | No dispute reported | 06/30/2026 | 1228855636 |
| Principal investigator 1 | ABBVIE INC. | $2,813.27 | 05/28/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202486355 |
| Principal investigator 1 | ABBVIE INC. | $364.50 | 05/28/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202486357 |
| Principal investigator 1 | ABBVIE INC. | $2,813.27 | 05/28/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202486359 |
| Principal investigator 1 | ABBVIE INC. | $126.00 | 05/28/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202486365 |
| Principal investigator 1 | ABBVIE INC. | $126.00 | 05/28/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202486367 |
| Principal investigator 1 | ABBVIE INC. | $2,589.84 | 05/28/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202486369 |
| Principal investigator 1 | ABBVIE INC. | $364.50 | 05/28/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202486371 |
| Principal investigator 1 | ABBVIE INC. | $126.00 | 05/28/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202486395 |
| Principal investigator 1 | ABBVIE INC. | $11,357.00 | 05/28/2025 | Non-covered Recipient Entity START MIDWEST LLC | A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1202486551 |
| Principal investigator 1 | Genmab U.S., Inc. | $5,723.19 | 05/26/2025 | Non-covered Recipient Entity START MIDWEST LLC | A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1235935498 |
| Principal investigator 1 | ABBVIE INC. | $27,193.64 | 05/23/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202486071 |
| Principal investigator 1 | ABBVIE INC. | $2,266.00 | 05/23/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202486083 |
| Principal investigator 1 | PFIZER INC. | $6,700.05 | 05/23/2025 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTITUMOR ACTIVITY OF PF07921585 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228855310 |
| Principal investigator 1 | PFIZER INC. | $40,223.14 | 05/23/2025 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07820435 AS MONOTHERAPY AND IN COMBINATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228856916 |
| Principal investigator 1 | ABBVIE INC. | $1,788.75 | 05/21/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202485531 |
| Principal investigator 1 | ABBVIE INC. | $4,267.84 | 05/21/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202485533 |
| Principal investigator 1 | ABBVIE INC. | $500.00 | 05/21/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202485539 |
| Principal investigator 1 | ABBVIE INC. | $5,000.00 | 05/21/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202485541 |
| Principal investigator 1 | ABBVIE INC. | $6,401.75 | 05/21/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202485543 |
| Principal investigator 1 | ABBVIE INC. | $2,133.92 | 05/21/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202485545 |
| Principal investigator 1 | ABBVIE INC. | $6,401.75 | 05/21/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202485547 |
| Principal investigator 1 | ABBVIE INC. | $270.00 | 05/21/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202485549 |
| Principal investigator 1 | ABBVIE INC. | $255.00 | 05/21/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202485551 |
| Principal investigator 1 | ABBVIE INC. | $2,133.92 | 05/21/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202485557 |
| Principal investigator 1 | ABBVIE INC. | $255.00 | 05/21/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202485561 |
| Principal investigator 1 | ABBVIE INC. | $67.50 | 05/21/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202485563 |
| Principal investigator 1 | ABBVIE INC. | $67.50 | 05/21/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202485565 |
| Principal investigator 1 | ABBVIE INC. | $790.00 | 05/21/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202485567 |
| Principal investigator 1 | ABBVIE INC. | $3,085.00 | 05/21/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202485577 |
| Principal investigator 1 | ABBVIE INC. | $510.00 | 05/21/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202485597 |
| Principal investigator 1 | ABBVIE INC. | $23,383.35 | 05/21/2025 | Non-covered Recipient Entity START MIDWEST LLC | A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1202485693 |
| Principal investigator 1 | ABBVIE INC. | $19,597.95 | 05/21/2025 | Non-covered Recipient Entity START MIDWEST LLC | A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1202485695 |
| Principal investigator 1 | ABBVIE INC. | $2,133.92 | 05/19/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202485399 |
| Principal investigator 1 | Ipsen Pharma SAS | $4,000.00 | 05/19/2025 | Non-covered Recipient Entity Cancer And Hematology Centers Of Western Michigan, Pc | A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants | No dispute reported | 06/30/2026 | 1184304885 |
| Principal investigator 1 | Ipsen Pharma SAS | $2,300.00 | 05/19/2025 | Non-covered Recipient Entity Cancer And Hematology Centers Of Western Michigan, Pc | A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants | No dispute reported | 06/30/2026 | 1184304887 |
| Principal investigator 1 | Ipsen Pharma SAS | $13,250.00 | 05/19/2025 | Non-covered Recipient Entity Cancer And Hematology Centers Of Western Michigan, Pc | A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants | No dispute reported | 06/30/2026 | 1184304889 |
| Principal investigator 1 | Ipsen Pharma SAS | $3,700.00 | 05/19/2025 | Non-covered Recipient Entity Cancer And Hematology Centers Of Western Michigan, Pc | A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants | No dispute reported | 06/30/2026 | 1184304891 |
| Principal investigator 1 | Ipsen Pharma SAS | $1,642.00 | 05/19/2025 | Non-covered Recipient Entity Cancer And Hematology Centers Of Western Michigan, Pc | A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants | No dispute reported | 06/30/2026 | 1184304893 |
| Principal investigator 1 | Ipsen Pharma SAS | $4,032.00 | 05/19/2025 | Non-covered Recipient Entity Cancer And Hematology Centers Of Western Michigan, Pc | A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants | No dispute reported | 06/30/2026 | 1184304895 |
| Principal investigator 1 | Ipsen Pharma SAS | $3,950.00 | 05/19/2025 | Non-covered Recipient Entity Cancer And Hematology Centers Of Western Michigan, Pc | A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants | No dispute reported | 06/30/2026 | 1184304897 |
| Principal investigator 1 | Ipsen Pharma SAS | $5,154.00 | 05/19/2025 | Non-covered Recipient Entity Cancer And Hematology Centers Of Western Michigan, Pc | A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants | No dispute reported | 06/30/2026 | 1184304899 |
| Principal investigator 1 | Ipsen Pharma SAS | $2,000.00 | 05/19/2025 | Non-covered Recipient Entity Cancer And Hematology Centers Of Western Michigan, Pc | A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants | No dispute reported | 06/30/2026 | 1184304901 |
| Principal investigator 1 | Ipsen Pharma SAS | $2,926.00 | 05/19/2025 | Non-covered Recipient Entity Cancer And Hematology Centers Of Western Michigan, Pc | A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants | No dispute reported | 06/30/2026 | 1184304903 |
| Principal investigator 1 | Ipsen Pharma SAS | $3,200.00 | 05/19/2025 | Non-covered Recipient Entity Cancer And Hematology Centers Of Western Michigan, Pc | A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants | No dispute reported | 06/30/2026 | 1184304905 |
| Principal investigator 1 | PFIZER INC. | $1,622.51 | 05/19/2025 | Non-covered Recipient Entity START Midwest | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228840258 |
| Principal investigator 1 | PFIZER INC. | $262.00 | 05/17/2025 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07820435 AS MONOTHERAPY AND IN COMBINATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228856220 |
| Principal investigator 1 | Genmab U.S., Inc. | $220.00 | 05/15/2025 | Non-covered Recipient Entity SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS | First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235935096 |
| Principal investigator 1 | PFIZER INC. | $4,642.42 | 05/15/2025 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228855318 |
| Principal investigator 1 | PFIZER INC. | $1,996.65 | 05/14/2025 | Non-covered Recipient Entity START Midwest LLC | AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B2 OPENLABEL STUDY TO INVESTIGATE TOLERABILITY PK AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT ARV471PF07850327 AN ORAL PROTEOLYSIS TARGETING CHIMERA IN COMBINATION WITH PF07220060 IN PARTICIPANTS AGED 18 YEARS AND OLDER WITH ERHER2 ADVANCED OR METASTATIC BREAST CANCER | No dispute reported | 06/30/2026 | 1228855349 |
| Principal investigator 1 | Genmab U.S., Inc. | $89,000.12 | 05/12/2025 | Non-covered Recipient Entity START MIDWEST LLC | A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1235935514 |
| Principal investigator 1 | ABBVIE INC. | $1,870.00 | 05/08/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202484175 |
| Principal investigator 1 | PFIZER INC. | $12,958.24 | 05/06/2025 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228855202 |
| Principal investigator 1 | PFIZER INC. | $39,707.55 | 05/06/2025 | Non-covered Recipient Entity South Texas Accelerated Research TherapeuticsLLC | FIRSTINHUMAN FIH OPENLABEL PHASE 1 DOSE ESCALATION AND EXPANSION STUDY DESIGNED TO EVALUATE THE SAFETY TOLERABILITY PK PD AND PRELIMINARY CLINICAL ACTIVITY OF PF07826390 AS A SINGLE AGENT OR IN COMBINATION TREATMENT FOR PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228855207 |
| Principal investigator 1 | PFIZER INC. | $2,581.20 | 05/06/2025 | Non-covered Recipient Entity START Midwest LLC | AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B2 OPENLABEL STUDY TO INVESTIGATE TOLERABILITY PK AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT ARV471PF07850327 AN ORAL PROTEOLYSIS TARGETING CHIMERA IN COMBINATION WITH PF07220060 IN PARTICIPANTS AGED 18 YEARS AND OLDER WITH ERHER2 ADVANCED OR METASTATIC BREAST CANCER | No dispute reported | 06/30/2026 | 1228855450 |
| Principal investigator 1 | ABBVIE INC. | $9,822.00 | 05/05/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202481051 |
| Principal investigator 1 | ABBVIE INC. | $935.00 | 05/05/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202481053 |
| Principal investigator 1 | ABBVIE INC. | $300.00 | 05/02/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202480909 |
| Principal investigator 1 | ABBVIE INC. | $1,050.00 | 05/02/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202480911 |
| Principal investigator 1 | ABBVIE INC. | $450.00 | 05/02/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202480913 |
| Principal investigator 1 | ABBVIE INC. | $1,400.00 | 05/02/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202480915 |
| Principal investigator 1 | ABBVIE INC. | $1,750.00 | 05/02/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202480917 |
| Principal investigator 1 | ABBVIE INC. | $550.00 | 05/02/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202480919 |
| Principal investigator 1 | ABBVIE INC. | $50.00 | 05/02/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202480921 |
| Principal investigator 1 | ABBVIE INC. | $2,813.27 | 04/30/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202480395 |
| Principal investigator 1 | ABBVIE INC. | $2,589.84 | 04/30/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202480405 |
| Principal investigator 1 | ABBVIE INC. | $364.50 | 04/30/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202480407 |
| Principal investigator 1 | ABBVIE INC. | $2,589.84 | 04/30/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202480409 |
| Principal investigator 1 | Genmab U.S., Inc. | $1,559.79 | 04/28/2025 | Non-covered Recipient Entity START MIDWEST LLC | A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1235935462 |
| Principal investigator 1 | PFIZER INC. | $7.50 | 04/28/2025 | Non-covered Recipient Entity START Midwest | A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228840180 |
| Principal investigator 1 | PFIZER INC. | $1,622.51 | 04/28/2025 | Non-covered Recipient Entity START Midwest | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228840252 |
| Principal investigator 1 | PFIZER INC. | $3,245.02 | 04/28/2025 | Non-covered Recipient Entity START Midwest | A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228840312 |
| Principal investigator 1 | PFIZER INC. | $8,885.70 | 04/24/2025 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTITUMOR ACTIVITY OF PF07921585 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228854571 |
| Principal investigator 1 | ABBVIE INC. | $29,166.75 | 04/18/2025 | Non-covered Recipient Entity START MIDWEST LLC | A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1202478146 |
| Principal investigator 1 | Stemline Therapeutics Inc. | $53,195.00 | 04/18/2025 | Non-covered Recipient Entity START MIDWEST, LLC | A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer | No dispute reported | 06/30/2026 | 1244134748 |
| Principal investigator 1 | Genmab U.S., Inc. | $32,539.06 | 04/15/2025 | Non-covered Recipient Entity START MIDWEST LLC | A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1235935518 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $107,315.60 | 04/09/2025 | Non-covered Recipient Entity Start Midwest | A Phase 1/1b First- in -Human Trial of BMS-986484 as Monotherapy and in Combination Therapies in Participants with Advanced Solid Malignancies | No dispute reported | 06/30/2026 | 1235993467 |
| Principal investigator 1 | PFIZER INC. | $630.70 | 04/08/2025 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228860123 |
| Principal investigator 1 | PFIZER INC. | $3,115.80 | 04/08/2025 | Non-covered Recipient Entity START Midwest LLC | AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B2 OPENLABEL STUDY TO INVESTIGATE TOLERABILITY PK AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT ARV471PF07850327 AN ORAL PROTEOLYSIS TARGETING CHIMERA IN COMBINATION WITH PF07220060 IN PARTICIPANTS AGED 18 YEARS AND OLDER WITH ERHER2 ADVANCED OR METASTATIC BREAST CANCER | No dispute reported | 06/30/2026 | 1228860505 |
| Principal investigator 1 | ABBVIE INC. | $1,788.75 | 04/07/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202474628 |
| Principal investigator 1 | ABBVIE INC. | $270.00 | 04/07/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202474632 |
| Principal investigator 1 | ABBVIE INC. | $1,998.00 | 04/07/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202474636 |
| Principal investigator 1 | ABBVIE INC. | $270.00 | 04/07/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202474639 |
| Principal investigator 1 | ABBVIE INC. | $2,338.20 | 04/07/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202474643 |
| Principal investigator 1 | ABBVIE INC. | $270.00 | 04/07/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202474647 |
| Principal investigator 1 | PFIZER INC. | $11,140.20 | 04/05/2025 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTITUMOR ACTIVITY OF PF07921585 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228855161 |
| Principal investigator 1 | PFIZER INC. | $251.78 | 04/05/2025 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07820435 AS MONOTHERAPY AND IN COMBINATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228856212 |
| Principal investigator 1 | Genmab U.S., Inc. | $56,715.62 | 04/04/2025 | Non-covered Recipient Entity SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS | First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235935150 |
| Principal investigator 1 | PFIZER INC. | $13,177.35 | 04/01/2025 | Non-covered Recipient Entity START Midwest LLC | AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B2 OPENLABEL STUDY TO INVESTIGATE TOLERABILITY PK AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT ARV471PF07850327 AN ORAL PROTEOLYSIS TARGETING CHIMERA IN COMBINATION WITH PF07220060 IN PARTICIPANTS AGED 18 YEARS AND OLDER WITH ERHER2 ADVANCED OR METASTATIC BREAST CANCER | No dispute reported | 06/30/2026 | 1228860113 |
| Principal investigator 1 | ABBVIE INC. | $3,152.25 | 03/31/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202467377 |
| Principal investigator 1 | ABBVIE INC. | $3,253.50 | 03/31/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202467382 |
| Principal investigator 1 | ABBVIE INC. | $3,152.25 | 03/31/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202467387 |
| Principal investigator 1 | ABBVIE INC. | $3,152.25 | 03/31/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202467391 |
| Principal investigator 1 | ABBVIE INC. | $2,589.84 | 03/31/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202467396 |
| Principal investigator 1 | ABBVIE INC. | $2,589.84 | 03/31/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202467412 |
| Principal investigator 1 | ABBVIE INC. | $3,711.15 | 03/31/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202467629 |
| Principal investigator 1 | ABBVIE INC. | $2,157.84 | 03/31/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202467633 |
| Principal investigator 1 | ABBVIE INC. | $364.50 | 03/31/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202467649 |
| Principal investigator 1 | ABBVIE INC. | $3,711.15 | 03/31/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202467654 |
| Principal investigator 1 | ABBVIE INC. | $2,060.10 | 03/31/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202467658 |
| Principal investigator 1 | ABBVIE INC. | $364.50 | 03/31/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202467661 |
| Principal investigator 1 | ABBVIE INC. | $364.50 | 03/31/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202467666 |
| Principal investigator 1 | ABBVIE INC. | $2,813.27 | 03/31/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202467670 |
| Principal investigator 1 | ABBVIE INC. | $2,813.27 | 03/31/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202467674 |
| Principal investigator 1 | ABBVIE INC. | $3,711.15 | 03/31/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202467685 |
| Principal investigator 1 | PFIZER INC. | $3,245.02 | 03/31/2025 | Non-covered Recipient Entity START Midwest | A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228840796 |
| Principal investigator 1 | PFIZER INC. | $7.50 | 03/31/2025 | Non-covered Recipient Entity START Midwest | A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228840882 |
| Principal investigator 1 | ABBVIE INC. | $2,589.84 | 03/24/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202465592 |
| Principal investigator 1 | ABBVIE INC. | $2,589.84 | 03/24/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202465597 |
| Principal investigator 1 | ABBVIE INC. | $2,589.84 | 03/24/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202465608 |
| Principal investigator 1 | ABBVIE INC. | $2,589.84 | 03/24/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202465611 |
| Principal investigator 1 | ABBVIE INC. | $2,713.37 | 03/24/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202465615 |
| Principal investigator 1 | ABBVIE INC. | $2,813.27 | 03/24/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202465621 |
| Principal investigator 1 | ABBVIE INC. | $2,589.84 | 03/24/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202465625 |
| Principal investigator 1 | ABBVIE INC. | $2,063.34 | 03/24/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202465629 |
| Principal investigator 1 | PFIZER INC. | $1,622.51 | 03/24/2025 | Non-covered Recipient Entity START Midwest | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228840824 |
| Principal investigator 1 | PFIZER INC. | $1,201.00 | 03/22/2025 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1 OPENLABEL STUDY OF PF07934040 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS HARBORING MUTATIONS IN THE KRAS GENE | No dispute reported | 06/30/2026 | 1228860572 |
| Principal investigator 1 | PFIZER INC. | $1,307.48 | 03/22/2025 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07820435 AS MONOTHERAPY AND IN COMBINATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228860612 |
| Principal investigator 1 | PFIZER INC. | $31,078.00 | 03/22/2025 | Non-covered Recipient Entity South Texas Accelerated Research TherapeuticsLLC | FIRSTINHUMAN FIH OPENLABEL PHASE 1 DOSE ESCALATION AND EXPANSION STUDY DESIGNED TO EVALUATE THE SAFETY TOLERABILITY PK PD AND PRELIMINARY CLINICAL ACTIVITY OF PF07826390 AS A SINGLE AGENT OR IN COMBINATION TREATMENT FOR PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228862091 |
| Principal investigator 1 | PFIZER INC. | $47,927.05 | 03/22/2025 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTITUMOR ACTIVITY OF PF07921585 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228862121 |
| Principal investigator 1 | Genmab U.S., Inc. | $16,898.00 | 03/21/2025 | Non-covered Recipient Entity START MIDWEST LLC | A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1235935446 |
| Principal investigator 1 | Genmab U.S., Inc. | $3,500.00 | 03/21/2025 | Non-covered Recipient Entity START MIDWEST LLC | A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1235935451 |
| Principal investigator 1 | Genmab U.S., Inc. | $17,300.00 | 03/21/2025 | Non-covered Recipient Entity START MIDWEST LLC | A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1235935454 |
| Principal investigator 1 | Genmab U.S., Inc. | $26,514.00 | 03/21/2025 | Non-covered Recipient Entity START MIDWEST LLC | A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1235935458 |
| Principal investigator 1 | ABBVIE INC. | $1,788.75 | 03/20/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202465398 |
| Principal investigator 1 | ABBVIE INC. | $270.00 | 03/20/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202465402 |
| Principal investigator 1 | PFIZER INC. | $20,917.27 | 03/14/2025 | Non-covered Recipient Entity START Midwest LLC | A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228862183 |
| Principal investigator 1 | PFIZER INC. | $1,135.26 | 03/14/2025 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228862325 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $24,840.00 | 03/13/2025 | Non-covered Recipient Entity South Texas Accelerated Research Therapeutics START Midwest | A Phase 1,1b Dose Escalation,Expansion Study of NGM438 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1232931906 |
| Principal investigator 1 | ABBVIE INC. | $6,000.00 | 03/12/2025 | Non-covered Recipient Entity START MIDWEST LLC | A Study of Adverse Events How Intravenously (IV) Infused ABBV-303 Moves Through the Body and Change in Disease State as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181) in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202462907 |
| Principal investigator 1 | ABBVIE INC. | $6,000.00 | 03/12/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202462911 |
| Principal investigator 1 | ABBVIE INC. | $1,050.00 | 03/10/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202462233 |
| Principal investigator 1 | ABBVIE INC. | $2,266.00 | 03/07/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202462130 |
| Principal investigator 1 | ABBVIE INC. | $500.00 | 03/06/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202458967 |
| Principal investigator 1 | ABBVIE INC. | $12,958.65 | 03/05/2025 | Non-covered Recipient Entity START MIDWEST LLC | A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1202456227 |
| Principal investigator 1 | PFIZER INC. | $1,480.95 | 03/04/2025 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTITUMOR ACTIVITY OF PF07921585 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228862194 |
| Principal investigator 1 | PFIZER INC. | $833.00 | 03/04/2025 | Non-covered Recipient Entity START Midwest LLC | PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY | No dispute reported | 06/30/2026 | 1228862317 |
| Principal investigator 1 | ABBVIE INC. | $3,354.75 | 02/28/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202455118 |
| Principal investigator 1 | ABBVIE INC. | $1,456.65 | 02/28/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202455122 |
| Principal investigator 1 | ABBVIE INC. | $1,456.65 | 02/28/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202455126 |
| Principal investigator 1 | ABBVIE INC. | $3,354.75 | 02/28/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202455129 |
| Principal investigator 1 | ABBVIE INC. | $1,776.60 | 02/28/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202455134 |
| Principal investigator 1 | ABBVIE INC. | $2,250.45 | 02/28/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202455148 |
| Principal investigator 1 | ABBVIE INC. | $3,152.25 | 02/28/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202455151 |
| Principal investigator 1 | ABBVIE INC. | $2,060.10 | 02/28/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202455156 |
| Principal investigator 1 | ABBVIE INC. | $3,152.25 | 02/28/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202455294 |
| Principal investigator 1 | ABBVIE INC. | $630.00 | 02/27/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202454829 |
| Principal investigator 1 | ABBVIE INC. | $1,020.00 | 02/27/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202454841 |
| Principal investigator 1 | PFIZER INC. | $42,534.45 | 02/25/2025 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTITUMOR ACTIVITY OF PF07921585 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228836810 |
| Principal investigator 1 | PFIZER INC. | $1,857.60 | 02/22/2025 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1 OPENLABEL STUDY OF PF07934040 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS HARBORING MUTATIONS IN THE KRAS GENE | No dispute reported | 06/30/2026 | 1228835330 |
| Principal investigator 1 | Genmab U.S., Inc. | $55.00 | 02/20/2025 | Non-covered Recipient Entity SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS | First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1235935072 |
| Principal investigator 1 | ABBVIE INC. | $58,853.80 | 02/19/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202452535 |
| Principal investigator 1 | ABBVIE INC. | $14,173.04 | 02/19/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202452539 |
| Principal investigator 1 | ABBVIE INC. | $4,267.84 | 02/19/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202452550 |
| Principal investigator 1 | ABBVIE INC. | $376.05 | 02/19/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202452554 |
| Principal investigator 1 | ABBVIE INC. | $2,133.92 | 02/19/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202452558 |
| Principal investigator 1 | ABBVIE INC. | $67.50 | 02/19/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202452587 |
| Principal investigator 1 | PFIZER INC. | $3,245.02 | 02/19/2025 | Non-covered Recipient Entity START Midwest | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228840831 |
| Principal investigator 1 | PFIZER INC. | $650.00 | 02/18/2025 | Non-covered Recipient Entity START Midwest | A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228840789 |
| Principal investigator 1 | PFIZER INC. | $6,490.04 | 02/18/2025 | Non-covered Recipient Entity START Midwest | A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228840818 |
| Principal investigator 1 | PFIZER INC. | $7.50 | 02/18/2025 | Non-covered Recipient Entity START Midwest | A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228840874 |
| Principal investigator 1 | ABBVIE INC. | $26,547.75 | 02/14/2025 | Non-covered Recipient Entity START MIDWEST LLC | A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1202451996 |
| Principal investigator 1 | PFIZER INC. | $1,996.65 | 02/14/2025 | Non-covered Recipient Entity START Midwest LLC | AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B2 OPENLABEL STUDY TO INVESTIGATE TOLERABILITY PK AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT ARV471PF07850327 AN ORAL PROTEOLYSIS TARGETING CHIMERA IN COMBINATION WITH PF07220060 IN PARTICIPANTS AGED 18 YEARS AND OLDER WITH ERHER2 ADVANCED OR METASTATIC BREAST CANCER | No dispute reported | 06/30/2026 | 1228836632 |
| Principal investigator 1 | PFIZER INC. | $39,176.40 | 02/14/2025 | Non-covered Recipient Entity START Midwest LLC | A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228836701 |
| Recipient | PFIZER INC. | $330.00 | 02/11/2025 | Covered Recipient Physician | PALBOCICLIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228829093 |
| Principal investigator 1 | PFIZER INC. | $4,192.00 | 02/05/2025 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07820435 AS MONOTHERAPY AND IN COMBINATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228835335 |
| Principal investigator 1 | PFIZER INC. | $650.00 | 02/03/2025 | Non-covered Recipient Entity START Midwest | A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228840165 |
| Principal investigator 1 | PFIZER INC. | $7.50 | 02/03/2025 | Non-covered Recipient Entity START Midwest | A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228840318 |
| Principal investigator 1 | ABBVIE INC. | $8,722.89 | 01/30/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202443292 |
| Principal investigator 1 | ABBVIE INC. | $6,401.75 | 01/30/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202443296 |
| Principal investigator 1 | ABBVIE INC. | $5,817.15 | 01/30/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202443300 |
| Principal investigator 1 | ABBVIE INC. | $11,630.52 | 01/30/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202443303 |
| Principal investigator 1 | ABBVIE INC. | $490.05 | 01/30/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202443309 |
| Principal investigator 1 | ABBVIE INC. | $6,776.19 | 01/30/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202443314 |
| Principal investigator 1 | ABBVIE INC. | $500.85 | 01/29/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442068 |
| Principal investigator 1 | ABBVIE INC. | $1,776.60 | 01/29/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442579 |
| Principal investigator 1 | ABBVIE INC. | $1,456.65 | 01/29/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442583 |
| Principal investigator 1 | ABBVIE INC. | $202.50 | 01/29/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442589 |
| Principal investigator 1 | ABBVIE INC. | $2,589.84 | 01/29/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442633 |
| Principal investigator 1 | ABBVIE INC. | $2,351.70 | 01/29/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442652 |
| Principal investigator 1 | ABBVIE INC. | $3,354.75 | 01/29/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442655 |
| Principal investigator 1 | ABBVIE INC. | $2,589.84 | 01/29/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442659 |
| Principal investigator 1 | ABBVIE INC. | $364.50 | 01/29/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442665 |
| Principal investigator 1 | ABBVIE INC. | $2,813.27 | 01/29/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442693 |
| Principal investigator 1 | ABBVIE INC. | $3,354.75 | 01/29/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442697 |
| Principal investigator 1 | ABBVIE INC. | $3,354.75 | 01/29/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442719 |
| Principal investigator 1 | ABBVIE INC. | $2,934.77 | 01/29/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442722 |
| Principal investigator 1 | ABBVIE INC. | $2,813.27 | 01/29/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442737 |
| Principal investigator 1 | ABBVIE INC. | $2,138.27 | 01/29/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442741 |
| Principal investigator 1 | ABBVIE INC. | $3,152.25 | 01/29/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442745 |
| Principal investigator 1 | ABBVIE INC. | $2,060.10 | 01/29/2025 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442806 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $12,588.95 | 01/29/2025 | Non-covered Recipient Entity CANCER AND HEMATOLOGY CENTERS OF WESTERN MICHIGAN, PC | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients with Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation | No dispute reported | 06/30/2026 | 1185541744 |
| Principal investigator 1 | Ipsen Pharma SAS | $70.00 | 01/28/2025 | Non-covered Recipient Entity Cancer And Hematology Centers Of Western Michigan, Pc | An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184304923 |
| Principal investigator 1 | Ipsen Pharma SAS | $60.00 | 01/28/2025 | Non-covered Recipient Entity Cancer And Hematology Centers Of Western Michigan, Pc | An Open-label, Phase I/II First-in-human, Dose Escalation and Confirmation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumour Activity of IPN01195 as Single Agent in Adult Participants With Advanced Solid Tumours | No dispute reported | 06/30/2026 | 1184304925 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $2,796.18 | 01/27/2025 | Non-covered Recipient Entity Start Midwest | A Phase 1/1b First- in -Human Trial of BMS-986484 as Monotherapy and in Combination Therapies in Participants with Advanced Solid Malignancies | No dispute reported | 06/30/2026 | 1235993465 |
| Principal investigator 1 | PFIZER INC. | $12,718.00 | 01/23/2025 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1 OPENLABEL STUDY OF PF07934040 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS HARBORING MUTATIONS IN THE KRAS GENE | No dispute reported | 06/30/2026 | 1228861583 |
| Principal investigator 1 | PFIZER INC. | $4,282.20 | 01/22/2025 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07820435 AS MONOTHERAPY AND IN COMBINATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228860564 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $17,103.60 | 01/15/2025 | Non-covered Recipient Entity Start Midwest | A Phase 1b/2 Study of BMS-986442 in Combination with Nivolumab or Nivolumab and Chemotherapies in Participants with Advanced Solid Tumors and Non-small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1235993461 |
| Principal investigator 1 | PFIZER INC. | $1,996.65 | 01/15/2025 | Non-covered Recipient Entity START Midwest LLC | AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B2 OPENLABEL STUDY TO INVESTIGATE TOLERABILITY PK AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT ARV471PF07850327 AN ORAL PROTEOLYSIS TARGETING CHIMERA IN COMBINATION WITH PF07220060 IN PARTICIPANTS AGED 18 YEARS AND OLDER WITH ERHER2 ADVANCED OR METASTATIC BREAST CANCER | No dispute reported | 06/30/2026 | 1228863198 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $9,412.21 | 01/10/2025 | Non-covered Recipient Entity Start Midwest | A Phase I/II First-in-human Study of BMS-986258 Alone and in Combination with Nivolumab in Advanced Malignant Tumors | No dispute reported | 06/30/2026 | 1235993463 |